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Abstract
This thesis deals with a polymer modification method for proteins, which is known as PEG-
ylation. It represents the covalent attachment of polyethylene glycol (PEG) to a target
molecule and is currently the state of the art technology to improve important characteristics
of biopharmaceuticals. Even though this methodology was developed forty years ago, there
still exist significant issues regarding process control and product purification. This work is
focused on the optimization of aforementioned aspects and is divided in two parts:
• Development of fast and high sensitive analytics for PEG-protein conjugates.
• Optimization of PEGylation reactions by means of the established analytics and high
throughput experimentation.
PEGylation reactions generally result in heterogeneous mixtures, if more than one acces-
sible binding site is available. Besides unmodified protein, the product mixture consists of
different PEG-protein conjugates varying in position and number of attached PEG molecules.
However, each conjugate can offer different characteristics affecting relevant clinical aspects,
including activity and stability. Consequently, characterization and purification of PEG-
protein mixtures is of high interest and mandatory for regulatory approval. However, the
separation especially of positional isoforms is still a challenging task.
As PEGylation target, lysozyme was used as model protein in this work, which consists of
six lysine residues. If the PEGylation reaction is applied with amino coupling PEG reagents,
such as PEG-aldehyde, multi-PEGylated conjugates and theoretically six isoforms of mono-
PEGylated lysozyme are generated. To separate PEG-protein conjugates, ion exchange
chromatography (IEC) can be applied, due to PEG binding and thus altered or shielded
surface protein charge. However, different PEGylation studies with PEGylated lysozyme
were not able to detect and separate more than three isoforms using IEC with a classical
salt gradient elution.
In a first step, a linear pH gradient was applied in this work to separate purified mono-PEG
lysozyme isoforms on a cation exchange column. In contrast to salt gradient chromatogra-
phy runs, five isoform were separated, representing a significant increase in resolution. To
identify the corresponding PEG attachment sites, the isoelectric point (pI) of each isoform
was calculated based on structural data using an in silico approach. For this, the assumption
that every PEG to amino residue conjugation neutralizes a positive charge was used. With
a comparison of elution pH values and the calculated isoelectric points the identification of
PEG attachment sites could be achieved. Based on UV areas it was possible to determine
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corresponding reactivities, additionally. Accordingly, the N-terminal amine at lysine 1 (in
the following labeled as PEG-lys1) exhibited the highest reactivity under neutral PEGy-
lation buffer pH values, followed by the lysine 33 residue. To verify the results, classical
peptide mapping and MALDI-TOF MS analytics were applied. In addition, it could be
shown that increased PEG molecular weight does not affect the isoform distribution, but
results in lowered elution pH values of corresponding isoforms.
In the following, the development of fast PEGamer analytics was conducted. In contrast
to PEG-conjugate isoforms, PEGamers vary in the number of attached PEG and can be
easily separated using size exclusion chromatography (SEC), due to different hydrodynamic
radii. However, using high throughput experimentation in modern downstream development,
automation, miniaturization and parallelization enable the generation of a large number of
samples. To guarantee a fast and efficient use of high throughput screenings, analytical
speed is consequently an important aspect. An increased sample throughput of existing
PEGamer analytics was achieved by a multivariate data analysis (MVDA). Based on the
data of five chromatograms, including native lysozyme, PEGamer variants (mono-, di- and
tri-PEGylated lysozyme) and a blank sample, different multivariate approaches were eval-
uated. The approaches were compared and multilinear regression (MLR) showed the most
precise calibrations. Applying this method, a precise assay for PEGamer quantification was
established with an analysis time of two minutes per sample.
The second part of this work covers the optimization of the PEGylation reaction in free so-
lution and the so called solid-phase PEGylation. Due significant influence of various process
parameters on PEGamer and isoform formation, high-throughput experimentation (HTE)
was applied to optimize the PEGylation reaction in free solution. For this, small scale
PEGylation experiments were conducted in 96-well microtiter plates with a total sample
volume of 300 µL. The reactions were carried out in different reaction buffers, to identify
the influence of different parameters such as buffer pH value and PEG excess. Applying an
automated sample generation, the influence of time on the model reaction could be evalu-
ated, by generating kinetics of mono-, di- and tri PEGylated species. With the established
isoform analytics, a significant impact of the buffer pH value on the isoform distribution
could be demonstrated. Accordingly, PEGylation occurs mainly at the N-terminal amino
residue, if buffer pH values around pH 6 are used, while the most reactive site at pH 8 is
lysine 33. This knowledge was used in the following to identify optimal process conditions
to achieve a maximum concentration of each isoform. In further experiments, Micrococcus
lysodeikticus based activity assays enabled the evaluation of the residual activity of result-
ing PEG-lysozyme isoforms. According to this, lysine 33 PEGylated lysozyme (PEG-lys33)
exhibited the highest residual activity, followed by PEG-lys1. To show the potential for
an industrial application, the established methods were combined and a control space for a
PEGylation reaction was defined, which allows a constant and optimal volumetric activity
of isoform mixtures.
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Besides the optimization of PEGylation reactions in free solution, the aspect of solid-phase
PEGylation was elucidated. This method represents the PEG modification of adsorber bound
protein and can provide advantages with respect to process control, as two unit operations
(PEG reaction and the first purification step) can be combined. Due to missing isoform
analytics, the influence of this method regarding an altered isoform distribution could not
be analyzed so far. Using automated sample generation with combined SEC and high sen-
sitive isoform analytics, differences between adsorber based lysozyme PEGylation and the
reaction in free solution regarding PEGamer kinetics and isoform formation were evaluated.
As adsorber matrices, a conventional cation exchange resin (SP Sepharose FF) and a grafted
resin type (SP Sepharose XL) were investigated. Lysozyme bound onto the adsorbent matri-
ces showed generally a reduced PEGylation reaction compared to reactions in free solution,
which was attributed to additional film- and pore diffusion. Additionally, an altered isoform
distribution could be demonstrated. In contrast to predominant PEGylations at lysine 1
and lysine 33 of lysozyme in liquid phase at pH 6, a main modification of opposite-located
lysine residues 97 and 116 was found for solid phase experiments. This result could be ex-
plained with binding orientations on corresponding adsorbent materials, as previous studies
showed a main binding site onto both adsorbent matrices between lysine 1 and lysine 33. An
increased activity of the isoform mixture due to a favorable isoform distribution using the
solid-phase PEGylation could thus not be achieved, as PEG-lys33 was investigated in previ-
ous studies to be the most active isoform. However, the important influence on important
aspects could be confirmed and has to be taken into account, if solid–phase PEGylation is
applied. Additional experiments showed an influence of the initial adsorber surface coverage
with bound lysozyme on the isoform distribution, which can be explained with sterically
hindered attachment sites, due to neighboring bound lysozyme molecules.
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Zusammenfassung
Die vorliegende Doktorarbeit befasst sich mit der als PEGylierung bezeichneten Methode,
bei der es sich um die kovalente Bindung von Polyethylenglykol (PEG) an ein Zielmoleku¨l
handelt. Obwohl diese Art der Modifizierung bereits seit Jahrzehnten erfolgreich in der phar-
mazeutischen Industrie, vor allem bei therapeutischen Proteinen, angewendet wird, bestehen
nach wie vor zahlreiche Probleme im Hinblick auf die Prozessfu¨hrung der PEGylierungsreak-
tion und die vollsta¨ndige Auftrennung der entstehenden Konjugate. Der Fokus der Arbeit
liegt auf der Entwicklung von Lo¨sungsansa¨tzen bezu¨glich der angesprochenen Problematiken
und ist in zwei Teilbereiche gegliedert:
• Etablierung von geeigneten hochauflo¨senden und hochdurchsatzfa¨higen chromatogra-
phischen Analytiken von PEG-Protein Konjugaten.
• Anwendung der entwickelten Analysemethoden zur Optimierung von PEGylierungsreak-
tionen mit Hilfe von Hochdurchsatzexperimenten und Untersuchung industrierelevanter
Fragestellungen.
Bei der Reaktion von PEG mit einem Zielprotein entsteht bei der Verfu¨gbarkeit mehrerer
Bindestellen eine Mischung aus verschiedenen Produkten, die sich in der Anzahl, aber auch in
der Position der gebundenen PEG Moleku¨le unterscheiden. Die Auftrennung der entstehen-
den Konjugate ist dabei ein wichtiger Bestandteil in der Herstellung und Charakterisierung
PEGylierter Proteine, da sich durch die vera¨nderte Bindung zwischen PEG und Protein
entscheidende A¨nderungen in klinisch relevanten Eigenschaften, wie zum Beispiel der Ak-
tivita¨t, ergeben ko¨nnen. Die vollsta¨ndige chromatographische Auftrennung von Positionsiso-
formen ist allerdings schwierig und konnte bei der gewa¨hlten Reaktion mit dem Modellprotein
Lysozym bisher nur unzureichend erzielt werden. Bei der Modifizierung von Lysozym mit
PEG-aldehyd ko¨nnen neben multi-PEGylierten Varianten insgesamt sechs Isoformen von
mono-PEGyliertem Lysozym gebildet werden, die sich aus sechs Aminogruppen in Form von
Oberfla¨chen Lysingruppen bzw. dem N-Terminus ergeben.
Durch die Bindung von PEG erfolgt eine Vera¨nderung bzw. eine Abschirmung der Ober-
fla¨chenladungen des Proteins, so dass die einzelnen PEG-Protein Konjugate mit Ionenchro-
matographie (IEC) aufgetrennt werden ko¨nnen. Wa¨hrend in bisherigen Vero¨ffentlichungen
bei der Aufreinigung von mono-PEGyliertem Lysozym auf einem Kationentauscher lediglich
drei Isoformen unter Verwendung eines Salzgradienten aufgetrennt werden konnten, wurde
im ersten Teil der Arbeit die Elution mit einem pH Gradienten durchgefu¨hrt. Hierbei konnte
eine deutliche Verbesserung der Auflo¨sung im Vergleich zu Salzgradienten beobachtet werden
und erstmals eine Auftrennung von fu¨nf der insgesamt sechs mo¨glichen Isoformen erfolgen.
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Um eine Zuordnung der getrennten Isoformen zu den jeweiligen PEG-Lysozym Bindestellen
zu erhalten, wurden anschließend auf Basis der Proteinstruktur die Berechnung der isoelek-
trischen Punkte (pI) aller mo¨glichen Isoformen durchgefu¨hrt. Durch eine Korrelation der
berechneten Werte mit den Elutions-pH-Werten konnte eine Zuordnung der Elutionspeaks
mit den jeweiligen Bindestellen des Lysozyms erfolgen. Dabei konnte der N-Terminus von
Lysozym bei einem neutralen pH-Wert des Reaktionspuffers als reaktivste Gruppe bei der
PEGylierungsreaktion ermittelt werden. Dieses Ergebnis konnten mit tryptisch verdauten
PEG-Lysozym Isoformen in Verbindung mit massenspektrometrischen Messungen (MALDI-
TOF MS) verifiziert werden.
Im weiteren Verlauf der Arbeit stand die Entwicklung einer Analytik fu¨r sogenannte
PEGamere im Vordergrund, die sich im Gegensatz zu Isoformen lediglich in der Anzahl
der gebundenen PEG Moleku¨le unterscheiden. Durch die unterschiedlichen hydrodyna-
mischen Radien der Konjugate kann die chromatographische Trennung der PEGamere in
der Regel mit Hilfe von Gro¨ßenauschlusschromatographie (SEC) erfolgen. Da durch die
Anwendung von Hochdurchsatzexperimenten in der modernen Prozessentwicklung von phar-
mazeutischen Proteinen mit Hilfe von Techniken wie Automatisierung, Miniaturisierung und
Parallelisierung eine große Anzahl an Proben generiert werden, wird der angewendeten Ana-
lytik ein hoher Stellenwert zuteil. Diese stellt allerdings ha¨ufig einen zeitlichen Engpass dar
und limitiert somit die Anzahl der zu untersuchenden Proben. Um die PEGamer Analytik
fu¨r effiziente Hochdurchsatzexperimente nutzen zu ko¨nnen, stand somit eine Reduzierung
der beno¨tigten Probenzeit im Vordergrund. Auf Basis der Daten von fu¨nf Reinstoffchro-
matogrammen bestehend aus unmodifiziertem Lysozym, Mono-, Di- und Tri-PEG-Lysozym
und einer Blindprobe, wurde eine Multivariate Daten Analyse (MVDA) durchgefu¨hrt. Hier-
bei kamen verschiedene Modelle zum Einsatz, die miteinander verglichen wurden. Dabei
lieferte der Ansatz u¨ber Multilineare Regression (MLR) die besten Ergebnisse, so dass mit
Hilfe dieser Methode ein pra¨zises Assay entwickelt werden konnte und eine deutliche Re-
duzierung der Probenzeit auf unter zwei Minuten pro Probe erzielt wurde.
Der zweite Teil der vorliegenden Arbeit befasst sich mit der Verbesserung des Prozess-
versta¨ndnisses der vorliegenden PEGylierungsreaktion in freier Lo¨sung und der Festphasen-
PEGylierung unter Zuhilfenahme der zuvor entwickelten Analytiken.
Aufgrund des großen Einflusses verschiedener Prozessparameter bei der PEGylierungsreak-
tion im Hinblick auf die PEGamer Bildung und Isoformenverteilung, wurde eine Optimierung
der Modellreaktion mit Hilfe eines Hochdurchsatzscreenings durchgefu¨hrt. Hierzu erfolgte
zuna¨chst eine Miniaturisierung der PEG-Lysozym Reaktion auf einen 96-well Mikrotiter-
platten Maßstab mit einem Gesamtvolumen von 300 µL. Die PEGylierungsreaktion wurde
in verschiedenen Reaktionspuffern durchgefu¨hrt, so dass der Einfluss der Reaktionsbedin-
gungen wie pH-Wert und PEG-U¨berschuss untersucht werden konnte. Zudem konnten
durch die automatisierte Probengenerierung Kinetiken bezu¨glich der Mono-, Di- und Tri-
PEG Lysozym Bildung aufgestellt werden, um so den zeitlichen Einfluss auf die Reaktion
zu beurteilen. Mit Hilfe der zuvor entwickelten Isoformenanalytik konnte des Weiteren
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die Isoformenverteilung von mono-PEGylierten Lysozym in Abha¨ngigkeit der untersuchten
Prozessparameter analysiert werden und ein deutlicher Einfluss des pH-Wertes festgestellt
werden. Demnach stellt der N-Terminus bei pH Werten von 6 die reaktivste Gruppe dar,
wobei bei pH 8 hauptsa¨chlich Lysin 33 PEGyliert wird. Damit konnten fu¨r jede Isoform
ideale Prozessparameter identifiziert werden, die eine maximale Konzentration ergeben. Die
Etablierung eines Aktivita¨tsassays basierend auf Micrococcus lysodeikticus ermo¨glichte es zu-
dem die spezifische Aktivita¨t der Isoformen zu ermitteln, wobei sich PEG-Lysozym33, gefolgt
von PEG-Lysozym1 als am aktivsten erwiesen. Durch die Kombination der entwickelten
Methoden konnte ein Bereich bestimmt werden, der eine konstante volumetrische Aktivita¨t
eines Gemisches von Isoformen gewa¨hrleistet und so eine optimale Prozessfu¨hrung von nach
wie vor zugelassenen PEG-Protein Isoformengemischen darstellt.
Neben der Optimierung der Reaktionen in freier Lo¨sung sollte auch die sogenannte Fest-
phasen-, bzw. on-column PEGylierung untersucht werden, die eine PEGylierung von bereits
immobilisiertem Zielprotein auf Adsorbermaterial darstellt. Dieses Vorgehen kann Vorteile
im Bezug auf die Prozessfu¨hrung darstellen, da zwei Prozessschritte (Reaktion und erster
Aufreinigungsschritt) kombiniert werden ko¨nnen. Aufgrund von fehlenden hochauflo¨senden
Analytiken konnte allerdings bisher der Einfluss der solid-phase PEGylierung insbesondere
auf die Isoformenverteilung nicht ausreichend untersucht werden. Wie bei der Reaktionen
in freier Lo¨sung wurden mit Hilfe einer Roboterstation miniaturisierte Reaktionsansa¨tze
hergestellt, bei denen Lysozym vor der PEGylierungsreaktion an verschiedene Adsorber-
typen immobilisiert wurde. Neben SP Sepharose FF, einem konventionellen Kationen-
tauscher, wurde mit SP Sepharose XL auch ein gegrafteter Adsorbertyp untersucht. Bei
beiden Adsorbertypen konnte eine deutlich geringere Reaktionsgeschwindigkeit zu PEG-
Protein Konjugaten ermittelt werden, die sich auf zusa¨tzliche Film- und Porendiffussion bei
den Adsorberpartikel zuru¨ckfu¨hren la¨sst. Des Weiteren konnte eine vera¨nderte Isoformen-
verteilung im Gegensatz zu den PEGylierungsreaktionen in freier Lo¨sung festgestellt werden,
die sich mit der entwickelten Isoformenanalytik untersuchen ließ. Wa¨hrend der N-Terminus
an Lysin 1 und Lysin 33 in freier Lo¨sung die HauptPEGylierungsstellen und somit die reak-
tivsten Gruppen darstellen, wurden bei den adsorbergebundenen Reaktionen hauptsa¨chlich
die gegenu¨berliegenden Gruppen Lysin 97 und Lysin 116 PEGyliert. Dieses Ergebnis kor-
reliert mit Studien u¨ber die Bindungsorientierung von Lysozym auf den entsprechenden
Adsorbern, bei denen die Hauptbindestelle zwischen Lysin 33 und Lysin 1 ermittelt wer-
den konnte, so dass es zu einer PEGylierung der gegenu¨berliegenden Lysin Reste kommt.
Da in den zuvor durchgefu¨hrten Aktivita¨tsassays PEG-Lysozym33 als aktivste Isoform er-
mittelt wurde, konnte mit Hilfe der Festphasen-PEGylierung somit keine ho¨here spezifische
Aktivita¨t des entstehenden Isoformengemisches erreicht werden. Allerdings konnte erstmals
der Einfluss auf die Isoformen und somit eventuell auch auf klinisch relevante Eigenschaften
nachgewiesen werden und die Bindungsorientierung von Lysozym auf den entsprechenden
Adsorbern besta¨tigt werden. Zusa¨tzliche Versuche mit variierender Oberfla¨chenbeladung
zeigten ebenfalls einen Einfluss auf die Isoformenverteilung und konnten mit sterischen Ef-
fekten durch benachbarte Lysozym Moleku¨le erkla¨rt werden.
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1 Introduction
1.1 Historical perspective of PEG-protein conjugation
Pioneering work in the field of protein modification with polyethylene glycol (PEG) was con-
ducted in 1977 by the group of Abuchowski and Davis [Abuchowski et al., 1977]. Although
PEG conjugation to proteins and surfaces were already done in the early 70s by numerous
research groups, including Merrill and Sehon [Merrill, 1992, Sehon, 1992], the experiments
by Abuchowski and Davis can be seen as a significant landmark.
As recombinant proteins were generally not available at this time, the initial intention
of their experiments was to enable the benefits of non-human bioactive proteins to humans,
without the severe immunological responses [Davis, 2002]. By injecting PEG-modified bovine
serum albumin (BSA) into rabbits, a reduced immunogenicity and enhanced blood circulation
half-life compared to the native form could be determined. The results were related to a
reduced proteolytic digestion of resulting conjugates due to the protective effect of attached
PEG and demonstrated the potential of this approach for pharmaceutical applications.
Although, other non-toxic polymers were also investigated in following years, PEG re-
mained the main conjugation reagent, as it was already being used in the food and cosmetics
industry. Additionally, PEG was designated by the FDA as “generally recognized as safe”
(GRAS), due to its use in the pharmaceutical industry, for example as solubilizing agent in
injectable therapeutics. The preparation of methoxy-PEG (mPEG) and thus the availability
of monofunctional molecules with only one activated terminal group was another positive
effect of PEG, reducing a diol formation and preventing a cross linkage between two proteins.
In 1990, Enzon Pharmaceuticals, which was founded by Abuchowski and Davis, achieved
the approval of the first PEGylated therapeutic by the regulatory authorities. This can
be seen as final breakthrough of the PEGylation technology, as it paved the way for sub-
sequent PEGylated therapeutics, only thirteen years after the first experiments. The new
drug was called Adagen R©, representing PEG-modified adenosine-deaminase and treated a
rare immunodeficiency disease (SCID) in children. In contrast to the unmodified form, the
PEGylated molecule was not readily cleared by the kidneys, due to increased size and it was
the first therapy for this disease.
Adagen R©, as well as Oncaspar R©, which was also a PEGylated enzyme and invented by
Enzon, reached only a limited number of patients, due to rare therapeutic indications. How-
ever, with the advent of humanized recombinant proteins the improved residence time of
PEGylated proteins became an interesting aspect for a large part of biopharmaceuticals.
Consequently, following approved PEG-modified therapeutics mainly achieved blockbuster
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Table 1.1: Approved PEGylated products in clinical practice. Data according to [Pasut and Veronese, 2012,
Veronese et al., 2009, Kang et al., 2009]
Target & Size and quantity Binding site Therapeutic Year to
tradename of PEG molecules indication market
Adenosine deaminase 5 kDa lysine
SCID 1990
Adagen R© 1 random
Asparaginase 5 kDa lysine
Leucemia 1994
Oncaspar R© 1 random
Interferon-α2b 12 kDa lysine, histidine
Hepatitis C 2000
PEG-Intron R© 1-2 random
Interferon-α2a 40 kDa lysine
Hepatitis C 2001
Pegasys R© 1 random
hGH antagonist 5 kDa N-terminus, lysine
Acromegaly 2002
Somavert R© 4-6 random
G-CSF 20 kDa N-terminus
Neutropenia 2004
Neulasta R© 1 selective
Anti-VEGF aptamer 2x20 kDa N-terminus
ADM 2004
Macugen R© 1 selective
Epoetin 30 kDa N-terminus, lysine
Anemia 2007
Mircera R© 1 random
Anti-TNF Fab 40 kDa thiol residue Rheumatoid
2008
Cimzia R© 1 selective arthritis
Uricase 10 kDa lysine Chronic
2010
Krystexxa R© 36 random gout
ADM: age-related macular degeneration; G-CSF: granulocyte-colony stimulating factor
SCID: severe combined immunodeficiency desease; TNF: tumor necrosis factor;
VEGF: vascular endothelial growth factor
status, representing sales over 1 billion US$ per year. Very successful PEG-protein conju-
gates include PEGylated interferon (Pegasys R©, from Hoffman-LaRoche) for the treatment of
hepatitis C and PEGylated granulocyte colony-stimulating factor (G-CSF, Neulasta R© from
Amgen) to treat leukemia. According to sales per year, both drugs were listed under the
100 most successful pharmaceuticals worldwide in 2010 [McGrath et al., 2010], indicating
a well-established technology with significant therapeutic value. Up to now, ten PEGy-
lated products are in clinical practice and are listed in Table 1.1. Except for Macugen R©,
representing a PEGylated RNA oligonucleotide, all of them are PEGylated proteins.
As can be seen, listed products vary in number and size of attached PEG, as well as the
PEGylation reaction, indicating a broad spectrum of modification techniques. In addition to
stated products, there are currently many different PEGylated molecules in various stages of
development, which are especially small parenteral administered molecules such as hormones
or antibody fragments [Fee and Van Alstine, 2011]. However, in spite of nearly forty years
of development, there still exist problems regarding process control and purification proce-
dures. The drawbacks comprise in particular preparative isoform separation and process
12
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reproducibility in terms of Quality-by-Design (QbD) and are discussed in detail in following
sections and manuscripts.
1.2 General benefits of PEGylated products
The elimination from blood of proteins with a molecular weight below the kidney threshold of
about 70 kDa (Mw based on protein mass) occurs mainly via renal clearance. Consequently,
small intravenously administered molecules of pharmaceutical interest generally offer short
in vivo half-life and rapid clearance and thus show poor therapeutic effect. To overcome this
drawback, the attachment of PEG can be applied, as already shown in the early experiments
by Abuchowski and Davis, where this technique enhanced the residence time of BSA. This
advantage can mostly be related to the increased hydrodynamic radius of formed conjugates,
resulting in a reduced filtration through the renal glomeruli. Thus, PEGylation offers a
possibility for small molecules to develop their therapeutic use, if an appropriate PEG size
is applied.
Besides the benefits for small molecules, the increase in size can also have positive effects
for larger molecules. In contrast to the native unmodified form, PEGylated species require
a less frequent dosing due to an enhanced in vivo half-life. For example interferon (IFN)
for the treatment of hepatitis C has to be injected three times a week to ensure a high drug
concentration. In contrast, the PEGylated version Pegasys R© has to be injected only once a
week, representing a less stressful administration for patients.
In addition to these aspects, PEGylated proteins can exhibit a reduced immunogenicity
and antigenicity due to suppressed proteolysis and recognition by the immune system. Al-
though the conformation of PEG after protein attachment is not completely elucidated, it
is assumed that a so called shielding effect prevents the drug from degradation by prote-
olytic enzymes, antibody recognition and uptake by phagocytes. This also results in an
extended drug residence time and enables the administration of molecules with increased
immunogenicity.
Another positive aspect of PEGylation can comprise a reduced aggregation propensity,
which is explained with masked hydrophobic patches on the protein surface by attached hy-
drophilic PEG. This allows high concentrated protein solutions without aggregation. Studies
by Chapman et al. [Chapman, 2002] observed for example a solubility of PEGylated anti-
body fragments up to 200 mg/mL, which represents an interesting option for the formulation
of proteins. The hydrophilic characteristics of PEG can also enhance the solubility of small
insoluble molecules including commonly used anticancer drugs such as docetaxel and pacli-
taxel [Kang et al., 2009]. Improved physical and thermal stability can be also detected for
PEGylated proteins, which is an important factor for formulation and delivery aspects.
1.3 Basic characteristics of PEG
Polyethylene glycol (PEG) is a polymer, consisting of covalently coupled ethylene oxide
subunits, each having a molecular weight of 44 Da. It is commercially available in linear, as
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well as branched forms and offers in its inactivated status hydroxyl residues at each terminus.
As these hydroxyl groups are less reactive, PEG can be functionalized, enabling different
conjugation reactions. There exist a large number of different PEG reagents, varying in
molecular weight and terminal residues at one or both ends. To prevent a cross linkage and
reduce diol formation, methoxy-PEG (mPEG) is generally used for protein conjugation.
As already mentioned, PEG can be provided with different average molecular weight.
However, as most synthetic polymers, PEG exhibits mainly a polydispersity, which can
be analyzed with high sensitive analytics such as MALDI-MS. As illustrated in Figure 1.3
varying PEG masses can be detected, all differing in the monomer mass of 44 Da. In spite of
this heterogeneity, PEG reagents up to 30 kDa with a polydisperse index of 1.05 are accepted
for pharmaceutical purposes.
H C    O  CH CH Active site
3 2 2
44 Da
MALDI-TOF MS analytics of PEG (5000 Da):
Linear methoxy-PEG structure:
n
Monomer M :
w
Figure 1.1: Illustration of a linear methoxy-PEG molecule (above) and a MALDI-TOF MS spectrum of
PEG5000-aldehyde, indicating the polydisperse nature of PEG (below).
While the ethylene moiety exhibits hydrophobicity, the oxygen allows a binding of about
6–7 water molecules, resulting in a good solubility in aqueous solutions, as well as many
organic solvents. Due to its strong hydration and flexibility, a PEG polymer in solution
offers a random coil structure. An improved synthesis by French et al. [French et al., 2009]
resulting in a monodisperse PEG with 16 subunits enabled a first PEG crystallization and
revealed secondary 310 helical structures.
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1.3.1 Toxicity and in vivo clearance
Although PEG is referred as non-biodegradable component, small PEG molecules can be
degraded in vivo by cytochrom P450 and aldehyde dehydrogenase. PEGs with a molecular
weight below 400 Da can be metabolized by alcohol dehydrogenase to toxic products. Larger
PEG molecules are eliminated mainly via renal pathways and are thus excreted by the
urine, if the molecular weight is below 40 kDa. Over the limit of the kidney threshold
of about 60 kDa, longer circulation as well as liver uptake can be detected and should
thus be avoided. Consequently, PEG reagents up to 40 kDa are currently used for protein
conjugation, representing a tradeoff between easy kidney clearance of PEG and improved
circulation time of the conjugate. Toxicity studies with high concentrated PEG solutions
revealed a formation of vacuoles in renal tubules cells in rabbits [Fruijtier-Po¨lloth, 2005].
Although the amount of administered PEG in PEG-protein pharmaceuticals is generally
below the concentrations applied in cited study, high dosages as a part of life long therapies
might thus be problematic.
Additionally, recent studies with PEG-uricase showed an anti-PEG immune response.
Numerous patients developed specific antibodies against PEG after the administration of the
drug, which puts the claimed immunogenicity of PEG into question [Armstrong et al., 2007].
1.3.2 Hydrodynamic radius
As already mentioned, the size of PEG and corresponding conjugates plays an important
role in drug clearing processes and consequently in the body residence time. To compare
the size of different molecules, their hydrodynamic radius or Stokes radius (Rh) is commonly
used, which represents the radius of a hypothetical hard sphere having the same diffusional
characteristics as the described molecule. Due to the bound water molecules and resulting
high flexibility, PEG offers an increased hydrodynamic radius compared to proteins with an
equivalent molecular weight. Consequently, the impact on size of attached PEG molecules
to proteins is higher, as might be expected from the PEGs nominal molecular weight.
The hydrodynamic radii of PEG molecules, as well as from proteins can be calculated based
on their molecular weight (Mw), given in daltons according to [Fee and Van Alstine, 2004]
and [Hagel, 1998]. Assuming a globular structure of the protein the hydrodynamic radius
Rh,protein in A˚ is given with Equation 1.1.
Rh,protein = (0.82± 0.02) Mw0.333 (1.1)
The correlation between the molecular weight of random coiled PEG in solution with its
hydrodynamic radius is given with Equation 1.2.
Rh,PEG = 0.1912 Mw
0.559 (1.2)
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Lysozyme
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Polyethelene glycol (PEG)
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PEG-lysozyme conjugate*
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Influence of PEGylation on the hydrodynamic radius
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h R : 3.05 nmhR : 1.99 nmh
Figure 1.2: Schematically illustration of lysozyme, a random coiled PEG-molecule and resulting PEG-
protein conjugate with corresponding hydrodynamic radii. Values were calculated according
to equation 1.1 to 1.4. *PEG-protein confirmation is not completely elucidated.
With Equation 1.3 and 1.4, the Stokes radius of a PEGylated protein can be predicted,
according to [Fee and Van Alstine, 2004].
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A
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) 1
2
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3
(1.4)
As the radius of the conjugate is independent of the number of attached PEG molecules,
Rh,PEG is calculated using the total PEG mass. To illustrate the size differences, Figure 1.2
shows the calculated hydrodynamic radii of lysozyme, a 5 kDa PEG molecule and resulting
conjugate. With a radius of 3.05 nm, the size of a mono PEGylated PEG5000-lysozyme
conjugate corresponds thus to a protein weight of 51.5 kDa, illustrating the significant impact
of PEGylation.
Up to now, the structural characteristics of PEG-proteins are not completely understood
and different models are discussed. The PEG confirmation after protein attachment is com-
monly described with a shell structure, where the protein is completely surrounded by PEG
chains. The PEG interacts with the protein via the hydrophobic ethylene units and cor-
responding patches on the protein surface [Morar et al., 2006]. Using this model, reduced
recognition by the immune system and improved aggregation behavior of PEG-protein con-
jugates can be explained. Alternative models suggest a worm-like structure of PEG with
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no PEG-protein interaction. Recent studies by Pai et al. [Pai et al., 2011] using small angle
neutron scattering (SANS), suggests a conformation, where a random coiled PEG molecule
is adjacent to the protein.
1.4 PEGylation strategies
The first PEG-protein reactions used by Abuchowski and Davis modified amino residues
using chlorotriazine activated PEG molecules. By now, there exist a large number of PE-
Gylation strategies, targeting different residues of surface amino acids. The most common
PEG conjugation technologies are listed below and are illustrated in Figure 1.3.
• Amino residue modification
The most commonly used PEGylation reactions for pharmaceutical therapeutics mod-
ify the amino residues of the target molecule including the α-amino residue (N-terminus)
and the -amino residues, such as lysine. For amino residue modification, different PEG
molecules can be applied, including PEG-aldehyde or N-hydroxysuccinimidyl (NHS)
activated PEGs. In addition to lysine residue PEGylation, PEG-NHS is also known to
react with histidine and tyrosine residues. Additionally, it is worth noting that acylat-
ing PEGs such as PEG-NHS can alter the charge of the target molecule by neutralizing
the positive charge of a lysine residue due to amide or urethane formation. Alkylating
PEGs including PEG-aldehyde maintain the charge. As lysine residues are generally
well represented in proteins, these kind of reactions often result in multi-PEGylation,
requiring additional purification. A positive aspect of PEG-aldehyde is given with the
possibility of a selective N-terminal PEGylation. Using mild acidic pH values of about
5–6, the N-terminal amino group can be PEGylated selectively due to its lower pKa
value, compared to the -amino residues.
• Enzyme mediated modification
Enzyme mediated PEGylation can be provided, targeting different surface amino acids.
Two main conjugation methods are established and are partially used for products in
clinical phases. To mimic natural glycosylation, so called GlycoPEGylation can be ap-
plied. For this, a two step conjugation is necessary, where the first step involves a glyco-
sylation of serine and threonine residues (O-glycosylation) with N-acetylgalactosamine
(GalNAc). The second step includes a subsequent PEGylation of glycosylated residues
with sialyl-PEG, using sialyltransferase. This method was successfully applied for
mono-PEGylated G-CSF and IFN, although both proteins offer numerous serine and
threonine residues. A recent study by Ostergaard et al. [Ostergaard et al., 2011]
demonstrated the PEGylation of already N-glycosylated proteins via asparagine residues.
Another possibility of enzyme PEGylation enables a glutamine residue modification
using transglutaminase (Tgase), which catalyzes the addition of a primary amine to
an acyl residue. Consequently, amino- PEGs (PEG-NH2) can be used as PEGylation
reagents for this reaction. As Tgase only recognizes glutamine residues that are located
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Figure 1.3: Different possibilities for protein PEG modification and corresponding PEG reagents. Illustra-
tion adapted from [Pasut and Veronese, 2012].
in exposed and flexible regions of the target molecule, this approach can thus be used
to reduce the number of positional isoforms. Studies with G-CSF, consisting of 17
glutamine residues resulted in a site-specifically mono-PEGylation, by applying this
method [Sato, 2002].
• Thiol residue modification
PEGylation of unpaired cystein residues can be conducted with PEG-maleimide, which
is already used in clinical practice for example to produce PEGylated anti-TNF anti-
body fragments (Cimzia R©). However, free cystein residues are generally not exposed
in natural proteins, as they are often involved in disulfide bridges. Thus, reducing con-
ditions are needed in case of antibody fragment PEGylation to prevent diol formation
and to enable a PEG conjugation. The integration of free cystein residues into the
amino acid sequence of a target molecule using genetic engineering, can provide the
possibility of a site specific PEGylation. However, this approach often leads to low
yields due to dimerization and incorrect protein folding [Basu et al., 2006].
• Disulfide bridging
A novel approach providing a selective PEGylation of interferon α-2b via a disulfide
bridge was first described by Shaunak et al. [Shaunak et al., 2006]. For this, a specific
mono-sulfone PEG reagent was used to perform a site selective PEGylation of both
cystein sulfur atoms via a so called three carbon PEGylation bridge. The disulfide
bridge involved in the conjugation was preserved, resulting in a correct conformation
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of the PEG-protein conjugate. An advantage of this approach is given with the small
number of disulfide bridges that are present in proteins of pharmaceutical interest.
1.5 PEGylation challenges and purification issues
As all therapeutic drugs, PEGylated proteins have to meet strict regulatory criteria with re-
spect to product homogeneity and activity. However, a large part of established PEGylation
reactions target more than one PEG attachment site, which generally results in a mixture
of conjugates, varying in number (PEGamers) and site (isoforms) of attached PEG chains.
These types of reactions are typically designated as random, due to the great influence of
process parameter on the product mixture. The quantity of PEGamers using random PE-
Gylation reactions is given with the available binding sites of the protein. The potential
number of positional isoforms (P) can be calculated according to the binominal coefficient
as follows:
P =
(
m
k
)
=
m!
(m− k)!k! (1.5)
where m is the number of available binding sites and k the number of modified sites
[Roberts et al., 2002]. For lysozyme as model protein in present work, amino coupling PEG
reagents can modify six residues. Consequently, six isoforms can be formed for mono-PEG-
lysozyme, and 15 for di-PEG-lysozyme, indicating a significant increase of isoforms with
increasing number of attached PEG molecules.
The variation in number and PEG-attachment sites yield conjugates with different product
characteristics, requiring purification after the PEG conjugation step. Additionally, the
target product has to be separated from unreacted PEG and other low molecular reaction
by-products. Due to difficulties in the chromatographic separation of positional isoforms,
characterized isoform mixtures are still allowed by the FDA, although they can exhibit
significant differences in important characteristics relevant to clinical effects.
An increase in product homogeneity can be provided by improved PEGylation reactions,
offering an increased specificity towards a single site, as described in the PEGylation reactions
section. However, the development of site-specific reactions is not trivial and fast approval
by the regulatory authorities might be problematic, especially for genetically introduced
binding sites. Another possibility includes reactions resulting in PEG-conjugate mixtures,
followed by an isolation of the target molecule and an effective removal of unwanted species.
To purify PEG modified proteins, differences in physicochemical properties such as size,
hydrophobicity and electrostatic charge can be used similar to unPEGylated proteins and
are discussed in the following.
• Size based separation
Due to increased size of PEG, the separation of PEGylated proteins and the native
19
Introduction
counterpart can be easily achieved via SEC and can be combined with a removal of
potential by-products, such as NHS. However, a good separation between PEG-proteins
with high PEG-extend becomes difficult with increasing number of attached PEG,
due to reduced differences in size and depends on the molecular weight of involved
components. Additionally, SEC is not suitable for the separation of PEG-protein
isoforms due to the same size of positional isoforms.
• Charge based separation
The shielding effect of PEG and thus blocked charge of the target molecule and in-
creased distance to chromatographic media allows a separation of PEGamers using
IEC. Multi-PEGylated species generally elute before di- and mono-PEGylated vari-
ants, followed by the native unPEGylated protein. As the position of attached PEG
can have a great influence on the proteins charge distribution, shallow salt gradients
can yield a separation of positional isoforms. Additionally IEC offers the advantage of
a PEG flow through while column loading, enabling a fast and effective PEG removal.
Due to the increased hydrodynamic radius of PEG and PEG-conjugates a drastic re-
duction in column loading, can be observed resulting in increased costs for column
media in PEG-protein purification.
• Separation based on hydrophobicity
As PEG interacts with HIC (hydrophobic interaction chromatography) media due to
its hydrophobic nature, free PEG of crude PEGylation mixtures interfere with the
separation, resulting generally in poor resolution performance. The elution order of
native protein and PEGylated species is not fixed and can vary with the applied buffer
salt [Mu¨ller et al., 2010].
Due to foaming and viscosity problems, a fast removal of free PEG is recommended for
the purification of PEG-protein mixtures. Various studies suggest that SEC followed by IEC
and HIC is a basis for a general PEG-purification process. Another possibility comprises the
use of two consecutive IEC separations. [Jevsevar et al., 2010]. In the first step, resins with
large particles and high porosity can be used to remove unreacted PEG, while the second
step is performed to achieve PEG-protein separation.
1.6 Current research trends in protein modification
Several research trends regarding PEGylation and protein modification can be observed over
the last few years and are briefly described in the following A large part of recently published
manuscripts are focused on the development of site specific-PEGylation techniques. Due to
separation and process challenges using random reactions, site-specific reactions are desirable,
offering a single and well-defined product. As already shown in the PEGylation reactions
section some promising reaction technologies are under development and are object of intense
research.
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Another topic includes releasable PEGylation especially for non-protein drugs enabling
the removal of the attached PEG after the administration. This could allow a controlled
release of the target drug without the disadvantage of reduced activity.
Due to PEG-antibody formation in some clinical studies, numerous conjugation alter-
natives have been also developed including HESylation which describes the attachment of
hydroxyethyl starch or PASylation, representing the conjugation of proline, alanine and ser-
ine. However, it remains questionable if these alternatives can compete with PEGylation in
terms of efficacy and acceptance.
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As already described the introduction, so called random PEGylation methods are widely
used to overcome particular limitations of biopharmaceuticals. In contrast to difficult site-
specific PEGylation methods, the random approach via surface amino acids provides a simple
PEG attachment without the need of an additional and complex modification of the target
protein. Due to accelerated approval procedures by the FDA, random PEGylation processes
enable a short time to market and underline the established status of this method. However,
as the term random already points out, this approach has distinct drawbacks. Although
“random” indicates an uncontrollable modification of available binding sites, the name is
rather derived from the significant influence of numerous process parameters on reaction
behavior and the PEG attachment site. Consequently, variations in reaction conditions
result in different heterogeneous product mixtures, with different isoform distributions, which
affects important clinical aspects. The difficult isoform separation complicates the analysis of
resulting mixtures, and thus the impact of corresponding parameters. This results in a lack
of process knowledge, hindering the development of an ideal process. The missing process
knowledge is also in contrast to regulatory guidelines, where well characterized processes and
defined parameter control spaces are mandatory for a reproducible product profile. Possible
disadvantages of random PEGylation processes consequently include the operation of the
process far from the optimum and batch rejects of already approved processes due variations
in product quality.
A possibility to improve such processes and to identify the influence of reaction parameters
is given with the concept of high throughput screening (HTS), which is often applied in the
downstream process development (DSP). Automated screening platforms enable an analysis
of large parameter sets, which allows a systematic understanding of the impact on the cor-
responding process. Combined with miniaturized sample reactions and fast analytics, HTS
can provide a fast optimization with minimal sample consumption. However, to achieve an
optimization of random PEGylation reactions using HTS, the development of appropriate
isoform analytics is a basic requirement.
At the beginning of this work, the main aim was consequently the development of high
sensitive analytics to investigate isoform distributions in PEG-protein mixtures. Due to
numerous studies with lysozyme and mPEG-aldehyde, this model reaction was chosen in
this context. Another objective was the miniaturization of PEGylation samples and the
automated sample preparation to provide sufficient data points for the screening of reac-
tion conditions. The combination of high throughput experimentation (HTE) with isoform
analytics should enable a deeper process understanding of the model reaction that results
in a rather directed and precise PEGylation of available binding sites, than a “random”
Research Proposal
modification. Another aspect in this work included the concept of on-column or solid-phase
PEGylation which represents an alternative PEGylation method in contrast to commonly
applied batch PEGylation reactions. With the obtained information about the impact of
PEGylation conditions in free solution, the adsorber based PEGylation should be evalu-
ated.
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1. Isoform separation and binding site determination of PEGylated lyso-
zyme using pH chromatography
Benjamin Maiser, Frieder Kro¨ner, Florian Dismer, Gerald-Brenner-Weiß, Ju¨rgen Hubbuch
In this paper the chromatographic separation of purified mono-PEG-lysozyme isoforms with
a pH gradient is described. Five of six possible isoforms were separated, which represents
a significant increase in resolution in contrast to classical salt gradient runs. Applying
a correlation between calculated isoelectric points (pI) of each isoform and their elution
pH value, PEG binding sites were identified. A common peptide mapping approach with
combined MALDI-MS analytics verified the results.
Published manuscript, Journal of Chromatography A, 1268, 102-108, 2012
2. Rapid quantification of protein-PEG conjugates by multivariate evalua-
tion of chromatographic data
Sigrid K. Hansen, Benjamin Maiser, Ju¨rgen Hubbuch
In this manuscript the development of a fast protein-PEG conjugate analysis is presented.
An increase in sample throughput was achieved by using high flow rates and small column
volumes. Multivariate calibration was applied to offset the reduction in resolution with
analytical speed. Additionally, a dynamic calibration approach was developed to account for
changes in column performance. Compared to different multivariate approaches multilinear
regression was found to be the most suitable method.
Published manuscript, Journal of Chromatography A, 1257, 44-47, 2012
3. Optimization of random PEGylation reactions by means of high through-
put screening
Benjamin Maiser, Florian Dismer, Ju¨rgen Hubbuch
This publication describes the implementation of high throughput process development
(HTPD) to the optimization of lysozyme PEGylation reactions. Applying PEGamer and
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isoform analytics introduced earlier by the authors, the influence of different reaction pa-
rameters on kinetics and isoform distribution was investigated. It could be demonstrated,
that different buffer pH values led to a main PEGylation of either lysine 33 or the N-terminus.
To show the potential for an industrial application, the parameter control space for maximal
volumetric activity was calculated with an additional enzyme activity assay.
submitted manuscript, Biotechnology and Bioengineering, 2013
4. Effect of lysozyme solid–phase PEGylation on reaction kinetics and iso-
form distribution
Benjamin Maiser, Florian Dismer, Ju¨rgen Hubbuch
In this manuscript, the concept of solid–phase PEGylation was applied using small scale PE-
Gylation experiments. It includes the influence of two different adsorber types on PEGamer
reaction kinetics and the isoform distribution compared to reactions in free solution. PEGy-
lation kinetics showed a significantly reduced reaction towards PEGylated species and the
altered isoform distribution showed a good correlation to lysozyme binding orientations on
corresponding resins.
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Abstract
Covalent attachment of PEG to proteins, known as PEGylation, is currently one of the
main approaches for improving the pharmacokinetics of biopharmaceuticals. However, the
separation and characterization especially of positional isoforms of PEGylated proteins are
still challenging tasks. A common purification strategy uses ion exchange chromatography
with increasing ionic strength by shallow salt gradients. This paper presents a method which
applies a linear pH gradient chromatography to separate five of six possible isoforms of mono
PEGylated lysozyme, modified with 5 kDa and 10 kDa mPEG-aldehyde. To identify the
corresponding PEGylation sites a comparison of elution pH values and calculated isoelectric
points of each isoform, was used. The resulting correlation showed an R2 > 0.99. Frac-
tionation, tryptic digestion and subsequent MALDI-MS analysis of each peak, verified the
predicted elution order. Based on UV areas the N-terminal amine at lysine 1 exhibited the
highest reactivity, followed by the lysine 33 residue.
Keywords: PEGylation, lysozyme, isoform separation, pH-gradient
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1 Introduction
Since the first PEGylation in 1977 by Abuchowski and Davis, polymer modification with
poly(ethylene glycol) (PEG) has become an important method to enhance the pharmaco-
logical properties of therapeutic biopharmaceuticals [1]. The covalent attachment of PEG
chains to a target molecule is well established and successfully used for numerous FDA ap-
proved proteins such as PEGylated interferon-α and erythropoietin (Pegasys R© and Micera R©
from Hoffmann LaRoche, respectively).
Advantages of polymer modification generally include increased circulation half-life and
a reduced immunogenicity of the conjugate compared to the unmodified form. Additional
positive effects of PEGylation can be an increased thermal stability as well as a higher
solubility which are also important for the therapeutics final formulation [2–4]. These changes
in the pharmacological behavior can mostly be explained with the increased hydrodynamic
radius of the conjugate and the resulting “shielding effect” of the attached PEG, which is
reviewed in detail by many publications [5–7].
For PEG attachment, various activated PEG agents and coupling strategies are commer-
cially available. Depending on the polymer modification, the attachment takes place at
different surface residues of the target molecule. A common chemistry for PEGylation tar-
gets accessible amino residues such as lysine or the N-terminus. For this, a modification with
succinimidyl activated PEGs (PEG-NHS) or PEG-aldehyde as shown in Figure 1, can be
applied. While PEG-NHS is capable of binding also with histidine and tyrosine residues, the
latter approach allows a main binding of PEG at the N-terminal α-amine at low pH values
and was chosen by Kinstler et. al. [8, 9] to develop polymer modified granulocyte colony
stimulating factor (G-CSF, Neulasta R© from Amgen).
ProteinH N
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Figure 1: PEGylation reaction with PEG-aldehyde and NaCNBH3 as reducing agent.
Reactions with target molecules that exhibit more than one accessible conjugation site,
result in randomly attached PEGs and thus in heterogeneous mixtures. The resulting prod-
uct consists of proteins with a different number of bound PEG and positional isoforms. Due
to steric hindrance of the attached polymer, changes in PEGylation degree and binding site
can have a major influence on biological activity of the different conjugates [10, 11]. With
only 7% residual activity compared to the native protein, Pegasys R©, a mixture of different
PEG-interferon (IFN) isoforms, shows how drastic this effect can be [12]. Additional experi-
ments with PEG-IFN showed a range of residual activity from 6% to 40% depending on the
binding site of the attached PEG [13]. The loss in activity is generally compensated by the
increased body residence time, but the high variance in activity underlines the influence of
the PEGylation site. Consequently, mixture characterization and isoform identification is of
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high interest and also needed for regulatory approval. Additionally, the selective PEGylation
either of a single site or the screening of reaction conditions towards favorable PEGylation
sites with high residual activity is preferred.
The separation of conjugate mixtures regarding the PEGylation degree can be achieved
effortlessly with size exclusion chromatography (SEC), due to the increase in size. Thus,
fast monitoring of crude PEG-protein mixtures combined with an improved data evaluation,
such as multivariate data analysis (MVDA) can be achieved by size based separation and
can be used in a first step to screen and optimize different PEGylation conditions [14]. A less
systematic approach for a lysozyme PEGylation optimization without an isoform analytic
was shown, for example, by Moosmann et al. [15].
However, the separation of isoforms with varying attachment site and the preparative
purification is challenging. Many approaches showed that ion exchange chromatography
(IEC) is an effective tool and currently the method of choice for conjugate and positional
isoform separation, by means of shallow salt gradients [16–18]. The different behavior is based
upon the shielding effect of attached polymer chains, and thus reduced interactions between
chromatographic matrix and protein. Additionally a decreasing protein surface charge with
an increasing number of bound PEG weakens the interaction with the oppositely charged
resin, which was already shown by Fee in an in silico approach [19]. Applying classical salt
gradient chromatography, different lysozyme PEGylation studies with PEG-NHS and PEG-
aldehyde showed that it was not possible to separate more than three isoforms, although
six isoforms are being formed during PEGylation. Even though some approaches showed
promising results, only little attention was paid to alternative ion exchange chromatography
with pH gradients [13, 20].
Besides the isoform separation, identification of PEG attachment sites is another chal-
lenge. Time consuming methods that are widely used comprise Edman degradation for
small peptides and peptide mapping with combined MALDI-TOF analysis [21–23]. The
mass spectrometric approach was applied by Lee and Park [21] for the characterization of
PEGylated lysozyme. For lysine residue modification the authors used biotin-PEG-NHS, to
separate PEG-peptide fragments from unmodified peptides, after tryptic digestion. Employ-
ing mass spectrometrical analysis of the peptide fragments, three positional isoforms with
different reactivities were identified.
The presented work describes the separation of mono-PEGylated lysozyme isoforms with
a linear pH gradient on a cation exchange column. In contrast to salt gradient chromatog-
raphy runs, a significant increase in resolution could be achieved and five of six possible
isoforms were separated. Based on the assumption that every PEG conjugation to amino
residues neutralizes an effective charge of the protein, a fast in silico approach was used to
calculate the isoelectric point of each isoform. The elution pH values were correlated with the
calculated isoelectric points to identify the PEGylation sites and to determine the isoform
reactivities. Peptide mapping and the common mass spectrometric approach were applied
to verify the results.
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2 Materials and methods
2.1 Chemicals
Sodium phosphate and sodium chloride for chromatography buffer and PEGylation buffer
preparation were obtained from Merck (Darmstadt, Germany). Hen egg white lysozyme
and sodium cyanoborohydride (NaCNBH3) were provided from Sigma-Aldrich (St. Louis,
MO, USA). Methoxy-PEG-propionaldehyde (mPEG-aldehyde) with an average molecular
weight of 5 kDa and 10 kDa was provided by NOF Cooperation (Tokyo, Japan). CABS
(cyclohexylamino-butansulfonic acid) with a pKa value of 10.7 was provided from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA) and was used as buffer substance for pH-
gradient chromatography. The calibration of the pH meter was performed with high precision
calibration standards from Hanna instruments (Woonsocket, RI, USA). The reagents for the
proteolytic digestion of the PEGylated protein, including ammoniumbicarbonate which was
used as the buffering substance, as well as dithiothreitol and iodoacetamide which were used
for the reduction and alkylation of the disulfide bonds, were obtained from Sigma-Aldrich.
Proteolytic digestion was prepared with proteomics grade trypsin from Sigma-Aldrich and
RapiGest surfactant (Waters Corporation, Milford, MA, USA). For the hydrolysis of the acid
labile surfactant trifluoracetic acid (TFA) from Sigma-Aldrich was used. For MALDI matrix
preparation α-cyano-4-hydroxycinnamic acid (CHCA) from Sigma-Aldrich and LC-MS grade
acetonitrile from Merck (Darmstadt, Germany) was used. Ultrapure water was generated
with the Arium pro water purification system from Sartorius Stedim (Goettingen, Germany).
All solutions used for chromatography were filtered using 0.2 µm cellulose acetate filters from
Sartorius Stedim (Goettingen, Germany) and degassed for 20 min in an ultrasonic bath.
2.2 Batch PEGylation reaction
Lysozyme (5 mg/mL) and mPEG-aldehyde with a molar polymer to protein ratio of 6:1
were dissolved in a 25 mM sodium phosphate buffer pH 7.2. containing 20 mM sodium
cyanoborohydride as reducing agent. The reaction was carried out in a continuously shaken
falcon tube at room temperature, for about 3.5 h. Monitoring of the PEGylation reaction
was conducted with size exclusion chromatography (SEC) using a Superdex 200 GL10/300
column on a A¨kta Ettan system (GE Healthcare, Uppsala, Sweden). For SEC 25 mM sodium
phosphate pH 7.2 containing 150 mM NaCl as mobile phase was used.
2.3 Analytical protocol
2.3.1 Separation of PEGylation degree
After the PEGylation reaction an IEC was used as a first chromatographic step to sepa-
rate the different PEGylation degrees and to stop the reaction. The reaction mixture was
separated with a Toyopearl GigaCap S-650M resin (Tosoh Bioscience GmbH, Stuttgart, Ger-
many) packed according to the manufacturer’s protocol into an Omnifit glas column (25 mm
x 400 mm, Diba Industries Ltd., Cambridge, UK). The resulting bed volume was 13.4 mL.
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The sample was diluted with ultrapure water (1:1) to reduce ionic strength. After column
equilibration with running buffer (25 mM sodium phosphate, pH 7.2), 50 mL sample mixture
was loaded onto the column. For elution a gradient ranging from 0 to 40 % of the elution
buffer (25 mM sodium phosphate, 500 mM sodium chloride, pH 7.2) was performed over
21 column volumes. The flow rate was maintained at 1 mL/min. To obtain mono-PEG
lysozyme samples, the fractionation volume was set to 5 mL. Until further measurement, the
fractions were pooled and stored at -32◦C.
2.3.2 Molecular weight determination
Peak fractions from IEC were analyzed by SEC with a light scattering (LS) detector. This
analysis was conducted using an A¨kta Ettan system from GE Healthcare (Uppsala, Sweden)
in combination with a Dawn Heleos 8+ multi-angle LS detector and an Optilap rEX refractive
index (RI) detector, both from Wyatt Technology (Santa Barbara, USA). The LS detector
was equipped with a fused silica cell and a laser with a wavelength of 658 nm. The LS
and RI detectors were calibrated with toluene and NaCl, respectively. The LS detector was
normalized using 2 mg/ml of bovine serum albumin (BSA) monomer from Sigma Aldrich,
as reference. For SEC a Superdex 200 GL10/300 (GE Healthcare, Uppsala, Sweden) with a
mobile phase of 25 mM sodium phosphate, pH 7.2, containing 150 mM NaCl was used. The
flow rate was set to 0.8 mL/min. Injection volumes between 50 and 100 µL were chosen.
After UV absorbance monitoring at 280 nm using the A¨kta UV-900 monitor, each sample
passed the LS and RI detectors. Correction of detector alignment and band broadening,
as well as molecular weight (Mw) calculation were done by the ASTRA software (software
version 5.3.4.18)
2.3.3 Separation of isoforms
Isoform separation was conducted on a MonoS 4.6/100 column from GE Healthcare (Upp-
sala, Sweden). Sample volumes between 100 µL and 150 µL of previously purified mono-PEG
lysozyme (modified with 5 kDa and 10 kDa mPEG) were chosen. For pH-gradient elution
20 mM CABS was used as buffer component. Running buffer A and elution buffer B were
titrated with 4 M NaOH to pH 10.5 and pH 11.5, respectively. The pH was measured
with a pH meter from Hanna Instruments (Woonsocket, RI, USA), calibrated from pH 10
to 12 with high precision calibration standards. The elution was carried out with a linear
gradient ranging from 0% to 100% buffer B over 12 column volumes. The flow rate was
set to 1.5 mL/min. To obtain samples for MALDI-TOF analysis the resulting peaks from
mono-PEG5.000-lysozyme isoforms were fractionated with a constant volume of 250 µL. The
fractions of multiple runs were pooled to reach sufficient amount of single isoforms for subse-
quent mass spectrometrical peptide mapping. The results of the pH gradient separation were
additionally compared with a classical salt gradient based cation exchange chromatography.
For salt gradient elution the same column, injection volume as well as gradient length were
used. As buffer system 25 mM sodium phosphate pH 7.2 was used. The elution was carried
out with a salt gradient reaching from 0 mM to 500 mM NaCl.
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2.3.4 Tryptic digestion of PEGylated lysozyme
After the chromatographic runs the collected fractions were transferred to VivaSpin 20 ul-
trafilters (Sartorius Stedim, Germany) with a molecular weight cutoff of 5 kDa and were
diafiltrated into 50 mM ammoniumbicarbonate buffer with pH 8.0 including 0.1 % (v/v)
RapiGest. Additionally the fractions were concentrated to the maximum degree and the
protein concentration was determined via UV 280 nm absorption measurement on a Infinite
M200 plate reader (Tecan, Maennedorf, Switzerland). The samples were then chemically
reduced by the addition of dithiotreitol up to a final concentration of 20 mM and denatured
for 30 minutes at 60◦C on a thermoshaker (Eppendorf, Hamburg, Germany). Alkylation
was carried out by adding iodoacetamide with a final concentration of 60 mM and mixing
the samples for 45 min on a shaker under exclusion of light. The prepared samples were
then digested with a trypsin to protein ratio of 1/2 - 1/10, depending on the sample protein
concentrations. The digestion was carried out at 37◦C over night. After the digestion, TFA
was added to a final concentration of 0.5 % (v/v) and the samples were incubated for another
45 minutes and then centrifuged to remove the RapiGest surfactant from the solution. The
samples were stored at -32◦C until measurement.
2.3.5 MALDI-MS based PEGylation site identification
To prepare samples for the final MALDI-MS measurement, they were processed with C18
ZipTips (Millipore Corporation, Billerica, MA, USA). The samples were bound to precon-
ditioned C18 ZipTips by pipetting and then eluted with the matrix solution, 10 mg/mL α-
cyano-4-hydroxycinnamic acid (CHCA) in 70% (v/v) ACN and directly spotted on a MALDI
stainless steel target. After drying the sample spots, MS analytics were analyzed in a MALDI
TOF/TOF 4800 analyzer (Applied Biosystems, Framingham, MA, USA). The mass spec-
trometer was run in positive, reflectron mode. Optimized device settings for the matrix
were used. The measured data was analyzed and exported using Data Explorer Software 4.0
(Applied Biosystems, Framingham, MA, USA). To identify the PEGylation site the masses
of the expected peptides were predicted with the PeptideCutter tool (Expasy - SIB Bioinfor-
matics Resource Portal), modified by the mass of the carbamidomethylation and compared
to the results of the single measurements. The PEGylated peptide fragment is heavier by
the mass of the PEG molecule (5008 Da) and could therefore be identified. Due to the poly-
dispersity of the PEG molecule the average mass of the measured fragment was determined
by “gauss-fitting” the resulting signal and determining the maxima of the fitted curve with
MATLAB (MathWorks, Natick, MA, USA).
2.4 pI calculation
Isoelectric point calculation of native lysozyme and PEGylated lysozyme isoforms were con-
ducted with the freely accessible web tool ‘protein continuum electrostatics’ (PCE). This
tool calculates pKa values of titratable groups in proteins solving the Poisson–Boltzmann
equation based on the MEAD (macroscopic electrostatics with atomic detail) program, devel-
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oped by Bashford [24, 25]. For pI calculation, the structural information of native lysozyme
(PDB-ID: 132L) obtained from the RSCB protein data bank was used. With resulting pKa
values, pI calculation was done applying the Henderson–Hasselbalch equation with Microsoft
Excel (Microsoft, Redmond, MA, USA). The pI value of each PEG-isoform was calculated
with neutralized lysine residues, involved in the conjugation.
3 Results and discussions
3.1 Lysozyme PEGylation degree
As PEGylation target the model protein lysozyme from chicken egg was used in this work.
According to the manufacturers datasheet it has a molecular weight of 14.3 kDa and an
isoelectric point of 11.3. Possible binding sites for the PEG-aldehyde reaction are six ly-
sine residues and the N-terminal amino group. The three-dimensional model, shown in
Figure 2, illustrates a lysozyme molecule and depicts that all lysine residues as well as the
N-terminus are located at the surface of the molecule, which can be explained with their
hydrophilic character. With the additional N-terminal amino group, lysine 1 contains two
binding sites. Consequently, PEGylation reactions with amino coupling PEG agents can
yield six mono-PEG lysozyme isoforms. However, different PEGylation studies with PEG-
NHS and PEG-aldehyde showed, that it was not possible to detect and separate more than
three isoforms [18].
180°
Lys 116 Lys 116
Lys 1
Lys 96
Lys 97
Lys 33
Lys 1
Lys 13
Figure 2: Two orientations of the three dimensional structure of lysozyme with labeled surface lysine
residues.
The PEGylation reaction was monitored using SEC, to optimize the reaction time towards
a high mono-PEG-lysozyme yield. In Figure 3 the SEC chromatograms of PEG-lysozyme
mixtures modified with 5 kDa and 10 kDa PEG-aldehyde, after 3.5 hours reaction time are
shown. The different elution volumes in each mixture result from the increase in size by
PEG attachment and indicates different PEGylation degree. As can be seen, di-PEG5.000-
and mono-PEG10.000-lysozyme conjugates have the same retention time in SEC, resulting
from the same hydrodynamic radius. This illustrates that the increase in size is only de-
pendent of the molecular weight and is regardless of the number of bound PEG, which was
already shown by Fee and Van Alstine [26]. As PEG-aldehyde is a non UV active component,
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Figure 3: SEC chromatograms of 5 kDa and 10 kDa PEGylated lysozyme mixtures after 3.5 h with a
Superdex 200 10/300 GL column and following elution order: di-PEG-lysozyme, mono-PEG-
lysozym and native lysozyme.
unreacted PEG was not detectable in the 280 nm UV trace.
For mono-PEG-lysozyme sample preparation, preparative purification of PEG-lysozyme
mixtures with ion exchange chromatography was applied, according to Moosmann et al. [27].
In addition to PEG-lysozyme conjugate separation, this method provides a removal of unre-
acted native protein as well as a flow through of unreacted PEG. Figure 4 depicts a resulting
chromatogram with a 5 kDa PEG-lysozyme mixture and shows a comparable elution be-
havior to SEC (see Figure 3). After peak fractionation, SEC with combined light scattering
was conducted with mono-PEG-lysozyme samples to verify purity and PEGylation degree.
The overall molecular mass of pooled mono-PEG5.000-lysozyme samples were calculated to
19.2 kDa with a protein fraction of 14.1 kDa. Calculated values of mono-PEG10.000-lysozyme
samples provided masses of 24.2 kDa and 13.9 kDa, respectively. SEC chromatograms of
purified mono-PEG-lysozyme samples showed no impurities of other PEGylation degrees
(data not shown).
3.2 Isoform separation
The isoform separation was conducted with purified mono-PEGylated-lysozyme samples,
modified with 5 kDa and 10 kDa PEG-aldehyde. In Figure 5 the resulting chromatograms
with salt gradient and pH gradient elution are shown. Five peaks could be detected in the
280 nm trace in the pH elution chromatogram, while salt gradient elution resulted in a sep-
aration of only three peaks. The different elution volumes of each peak can be linked to
altered surface charge due to different PEGylation sites. As only pure mono-PEG lysozyme
samples were injected, each peak represents lysozyme with one bound PEG chain attached
to a different amino residue. Even though lysozyme consists of six possible conjugation sites,
as mentioned before, only five isoforms were detected. The separation of a 10 kDa PEG
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Figure 4: Chromatogram of preparative purification of 5 kDa PEG-lysozyme mixture, using a GigaCap 650S
ion exchange adsorber. PEGylation degree was validated with SEC-LS.
modified lysozyme sample showed lower elution pH values, but the same elution pattern
compared to mono-PEG5.000-lysozyme.
3.3 Isoform identification
In pH gradient chromatography the elution of proteins is based on a decreasing surface
charge, which results in a decreasing strength of interaction between the adsorbed proteins
and the oppositely charged adsorber. Thus, resulting elution pH values correlate sometimes
with the proteins isoelectric point [28]. In classical salt gradient chromatography the proteins
are eluted due to an ion exchange process. This difference leads to salt and pH gradient
elution strategies, which can result in a different separation performance. To indicate the
elution order of the separated isoforms, pI calculations were performed with the PCE tool
from Miteva et al. [29]. Applying the described method, the pI for native lysozyme was
calculated as 11.28, with a good correlation to already published values by Ahamed et al.
[28].
The altered charge of the lysine residues caused by attaching a PEG molecule was taken as
a basis for the isoform pI calculations. Assuming that every PEG conjugation to the primary
amine of a lysine residue neutralizes the positive charge, surface net charge, isoelectric point
and also elution pH are reduced compared to native lysozyme. For isoform pI calculation of
PEG-lysozyme, lysine pKa values involved in the conjugation were ignored. Titration curve
calculations, using the Henderson-Hasselbalch equation to determine the proteins pI, were
applied regardless of the attached PEG molecular weight. Comparing the elution pH values
with the calculated isoelectric points, a peak identification to corresponding binding sites
as shown in Table 1 was conducted. The isoform with PEG binding site lysine 33 (in the
following labeled as PEG-lys33) exhibited the lowest calculated pI and was assigned to the
peak with the lowest elution pH. As lysine 97 and 116 exhibited the same calculated pI, these
isoforms were assumed to elute in one peak. The isoform elution sequence obtained from pI
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Figure 5: Chromatogragraphic separation of PEG-lysozyme isoforms using a pH gradient with a pH rage
from 10.5 to 11.5 (A) and a salt gradient from 0 mM to 500 mM NaCl in 25 mM phosphate buffer,
pH 7.2 (B) on a Mono S 4.6/100 column. The peak labels correspond to different positional
isoforms.
calculation results, starting with the lowest elution pH, was as follows: PEG-lys33, PEG-lys1,
PEG-lys96, followed by PEG-lys97 and PEG-lys116 eluting in one peak and PEG-lys13 eluting
last.
Figure 6 depicts the obtained results and shows that native lysozyme eluted roughly at its
isoelectric point. PEG-isoforms eluted earlier and at lower pH values than native lysozyme, as
expected. Additionally the elution volume of both PEG species correlated with an R2 > 0.99
to the calculated pI values. However, the elution pH of 10 kDa-PEG isoforms and 5 kDa-
PEG isoforms were shifted to lower pH values, indicating a lower interaction to the adsorber
matrix with increasing PEG weight.
In addition to reduced net charge, attached PEG chains might weaken the interaction of the
isoforms to the adsorber matrix, due to steric hindrance. This effect is probably dependent on
the attached molecular PEG weight. An increased protein-resin distance, might thus explain
the differences in the elution behavior of mono-PEG5.000- and mono-PEG10.000-lysozyme
isoforms. A study by Abe et al. [10] investigated this effect for ion exchange chromatography
and can be used for a detailed view of PEG-protein binding mechanisms. By comparing the
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Table 1: Elution pH values of separated mono-PEG-lysozyme isoforms and corresponding calculated isol-
electric points. Calculation of isoelectric points were applied with pKa values based from PCE-tool.
Binding Calculated Elution pH
site pI 5 kDa 10 kDa
lys 33 11.07 10.94 10.88
lys 1 11.12 10.99 10.92
lys 96 11.18 11.03 10.98
lys 97
11.27 11.11 11.05
lys 116
lys 13 11.28 11.13 11.08
native lysozyme 11.28 11.23
10,8 10,810,9 10,911,0 11,011,1 11,111,2 11,211,3 11,3
10,8 10,8
10,9 10,9
11,0 11,0
11,1 11,1
11,2 11,2
11,3 11,3
mono
5.000
-PEG-lysozyme
mono
10.000
-PEG-lysozyme
native lysozyme
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Figure 6: Plotted elution pH values of mono-PEG-lysozyme isoforms (left: modified with 5 kDa, right:
modified with 10 kDa) and native lysozyme versus calculated isoelectric points.
UV areas of each isoform, the reactivity of the different binding sites was evaluated. Thus,
PEGylation with 5 kDa and 10 kDa PEG occurs preferentially at lys 1, followed by lys 33
using the described reaction conditions. Only small reactivities were found for lysine 97, 116
and 96.
3.4 MALDI-MS analysis
To verify the conducted binding site identification, peptide mapping in combination with
mass spectrometric analysis was applied. The common procedure involves a tryptic digestion
of the isoform mixture and the comparison of the resulting peptides with the peptide pattern
of a digested native protein solution. Considering trypsin is sterically blocked by attached
PEG molecules, missing peptides refer to PEG-conjugation sites.
Instead of analyzing the peptide pattern, we decided to investigate the mass of the PEG-
peptide fragments. Lysozyme peptides resulting from tryptic digestion, hydrolyzed at lys 1
or lys 97 consist of only one amino acid and are consequently difficult to detect within the
signals of the used MALDI matrix. With the analysis of the heavier PEG-peptide fragments,
this problem was avoided. Analyzing unbound PEG-aldehyde samples with the described
Publications and Manuscripts
37
Table 2: PEG binding site, resulting mass of peptide-fragments and measured mass of PEG-peptide frag-
ments of mono5000-PEG-lysozyme isoforms. Theoretical mass of each PEG-peptide-fragment was
calculated with a PEG weigth of 4990 kDa and corresponding peptides.
Peak PEGylation Peptide PEG-peptide
number site mass [m/z] fragment mass [m/z]
expected measured
1 Lys 33
22-33 34-35
1325.63 1428.65 7744 7697
2 Lys 1
1 2-5
147.11 478.28 5615 5619
3 Lys 96
74-96 97
2508 147.11 7645 n/A
4
Lys 116
115-116 117-125
307.14 1045.54 6343 6352
Lys 97
97 98-112
147.11 1675.80 6813 n/A
5 Lys 13
6-13 14 15-21
893.42 175.12 874.42 6933 6854
MALDI-TOF analytics the polydisperse character of the polymer was obvious, which is
caused by the production process. Pure PEG samples showed a normally distributed signal
which was composed of single mass peaks. Each peak showed differences in weight of 44 Da,
indicating PEG chains with a different number of monomer units. Fitting the PEG sample
peaks using a gaussian fit function in MATLAB R©, the calculated average molecular mass was
5031 Da. The quality analysis by the PEG supplier provided an average weight of 5008 Da
for the same charge, confirming the used fitting method.
Four PEG-peptide fragments were detected in the separated and fractionated PEG-lysozyme
isoform samples. Mass differences between the mass peaks in each detected PEG-peptide
signal were 44 Da and refer consequently to PEG. The PEG-peptide fragments, detected in
isoform fractions PEG-lys33 and PEG-lys1 are shown in Figure 7, with the corresponding
calculated gaussian fits and peak maxima. Weight differences between the two fragment
signals can be noticed, which are caused by different peptide masses due to varying PEG
binding sites.
Calculated theoretical PEG-peptide fragments and evaluated average masses of analyzed
PEG-peptide signals are listed in Table 2 and assigned to their corresponding binding sites.
For calculating the theoretical total PEG-peptide mass, the PEG suppliers weight specifi-
cation was used and the mass of one water molecule was subtracted. A good agreement
of theoretical and the measured masses of the first two peaks, labeled as PEG-lys33 and
PEG-lys1 can be noticed. Considering baseline separation was provided between these peaks
the proposed peak identification was validated.
Peak 3, labeled as PEG-lys96 contained no detectable PEG mass peaks. Due to small
sample concentrations, a detection of the PEG-peptide signal was not possible. In addition,
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peak maximum
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Figure 7: MALDI-TOF spectra with PEG-peptide fragments of two 5 kDa PEG-lysozyme isoforms. Spectra
correspond to lysozyme with bound PEG at lysine 33 (PEG-lysozyme33) and lysine 1 (PEG-
lysozyme1), respectively
.
the small resolution to peak 2, hindered the fractionation of sufficient sample volume.
Instead of two PEG signals in peak 4, only one PEG-peptide fragment was found. With
an average weight of 6352 m/z the measured signal corresponds well to the theoretical PEG-
peptide mass of 6343 m/z of the proposed lys 116 binding site.
In peak 5, labeled as PEG-lys13 a theoretical PEG-peptide weight consisting of two pep-
tides and attached PEG could not be found. Thus, the corresponding PEG-peptide mass
was corrected assuming a sterical hindrance of PEG blocking the tryptic digestion between
lys 13 and arg 14 additionally. The resulting expected fragment weight of 6933 m/z agreed
then with the measured average weight of 6854 m/z. Comparing the mass peaks of the last
isoform peak, it can be noticed that the measured mass of 6854 m/z is between the expected
weight of binding site lys 97 and lys 13. Therefore, the proposed lys 13 binding site of peak 5
could not be validated by MS analytics.
A comparison of the findings using MS analytics with the alternative in silico binding
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site identification showed a good correlation and demonstrates the applicability of this fast
method. Lysozyme PEG binding site identifications were already conducted by numerous
authors including Lee et al. and Tilton et al. [21, 30], using MS analytics. Studies by Lee
et al. suggest lysine 33, lysine 97 and lysine 116 as major PEG binding sites, using a PEG-
NHS modification. Tilton applied a PEG-aldehyde reaction and proposed a predominant N-
terminal (lysine 1) modification of mono-PEG-lysozyme, with slight modifications at lysine
residues 33 and 97. This suggests a major influence of the coupling reaction to the resulting
PEG conjugation site. By comparing the results made in this study with results published
by Tilton with the same PEG reaction, a good agreement regarding the lysine reactivities
can be detected. In addition both results corresponds with the fact that main attachment
of PEG-aldehyde primarily occurs at the N-terminal amino group at low buffer pH values.
4 Conclusion and outlook
In this paper the separation of five positional isoforms of mono-PEGylated lysozyme is shown,
and thus represents an increase in resolution compared to published results. By applying a
pH gradient elution, we were able to achieve a superior resolution in contrast to classical salt
gradient runs, which underlines the high separation performance of pH gradients regarding
charge variant separation. An isoform elution order and the resulting PEG conjugation sites
were identified, using a fast in silico approach. The resulting reactivities of the identified
lysine residues were evaluated, and showed a good agreement to comparable PEG reactions
[30]. To validate the proposed binding site results, common MS analytics were applied. The
usability of the in silico binding site identification application was only shown for PEG-
lysozyme. With the presented chromatographic method, the evaluation of lysozyme isoform
reaction kinetics are possible and are already under investigation. In addition, on-column
PEGylation experiments can now be conducted and analyzed for changes in lysozyme binding
orientations.
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Abstract
Size exclusion chromatography (SEC) is often applied for characterization protein-poly-
ethylene glycol (PEG) conjugates regarding the number of attached PEG chains (PEG-
amers). SEC analysis is advantageous as it is precise, robust, and straightforward to estab-
lish. However, most SEC based assays have a maximal throughput of a few samples per
hour. We present a strategy to increase analytical throughput based on combining a short
column with a fast flow rate, and finally multivariate calibration in order to compensate
for the resolution lost in the trade off for speed. Different multivariate approaches were
compared and multilinear regression was shown to result in the most precise calibrations.
Further, a dynamic calibration approach was developed in order to account for changes in
column performance over time. In this way, it was possible to establish a highly precise assay
for protein PEGamer quantification with a throughput of 30 samples per hour.
Keywords: multivariate calibration; high throughput analytics; high throughput
experimentation; PEGamer quantification; protein PEGylation; high throughput
process development
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1 Introduction
Attaching polyethylene glycol (PEG) polymer chains to proteins (PEGylation) has been
shown to improve their pharmacokinetics. The increase in size reduces renal clearance of the
therapeutic and there is proof of immunogenicity and antigenicity being reduced by PEGy-
lation [1, 2]. Further, solubility of hydrophobic proteins can be increased by PEGylation [3].
The PEGylation process determines the number (PEGamers) and positions(isoforms) of the
PEG molecules attached to the protein. If random PEGylation is performed, the product of
the reaction will be very heterogeneous. This poses a problem in a regulative environment
which demands extremely high homogeneity of well defined products. In general, there are
two ways to reach a homogeneously PEGylated product. Either the product mixture of the
random PEGylation can be purified to contain only the desired PEGylated species or site
specific PEGylation can be performed.
In our lab, small scale PEGylation experiments performed automated on liquid handling
stations have been established. This enables high throughput screenings of PEGylation pro-
cess parameters and is a part of a general trend where automated high throughput experi-
mentation (HTE) is applied for high throughput process development (HTPD) of biologicals
[4]. For the evaluation of the performed experiments to stand in relation to experimen-
tal speed when performing HTE, the analytical throughput must match the experimental
throughput. In some cases this comes easily, for instance if the evaluation of screenings per-
formed in HTE mode can be based merely on univariate spectroscopic measurements such
as total protein quantification via UV absorption measurements [5–7]. If selective or specific
quantification is necessary, other methods have to be considered. In the case of quantitative
separation of protein PEGamers, size exclusion chromatography (SEC) is widely applied.
However, for SEC based assays to match the speed of HTE, the analysis time per sample
must be reduced to merely a few minutes.
SEC is a standard method for selective and specific quantification of proteins. If exact
quantification is the primary objective, most analysts will seek to achieve high resolution (R
> 1.5) of the components. If a short analysis time is the primary objective, faster flow rates
and/or shorter columns can be applied, however, at the expense of resolution. One approach
to increase analytical speed without losing resolution is the interlacing of injections and/or
parallel operation of two columns on a chromatographic system [8, 9]. When interlaced
injections are performed in SEC analysis, the result is elimination of initial lag time between
sample injection and start of elution. If interlaced injections are combined with parallel
operation of two columns, the waiting time post elution of the smallest sample molecule of
interest can be reduced or even eliminated. Thus, in favorable situations, analysis time per
sample can be reduced to the time span in which the molecules of interest elute.
The separation of protein PEGamers using SEC poses a very challenging task, as the
relative increase in molecular size decreases for each additional PEG molecule attached to
the protein [10]. A size based chromatographic separation of native protein and mono-
PEGylated species might be achieved effortlessly, however a resolution of the higher protein
PEGamers will become increasingly difficult.
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Our proposition is that for analytical purposes the degree of separation necessary for
correct quantification can be decreased significantly by applying alternative methods for the
evaluation of chromatographic data. This idea is based on the assumption that overlapping
elution of different species will result in a chromatogram which is a linear superposition
of the signals of each single analyte. Therefore, a linear multivariate correlation between
elution profile (chromatogram) and amounts of the different components in the respective
samples can be expected. This, of course, presumes that the amount of the analytes does
not influence the elution profile. In analytical chromatography, which is mostly performed
in the linear range of adsorption, this assumption would apply. Further, the separation
mechanism of SEC does not depend on direct interaction with the column material and thus
it is not expected that different load concentrations should cause a non-linear change of the
elution profile. If the linear correlation between analyte concentration and elution profile
is given, it should be possible to calibrate a multivariate regression model based solely on
chromatograms of each pure component. Such a multivariate regression model could then
give precise determinations of sample composition despite low chromatographic resolution
of the sample components.
The presented work describes how multivariate calibration can be used to gain quantitative
results of high quality from low resolution chromatograms. By doing so, faster analysis times
are achievable through application of short columns and high flow rates that would otherwise
be avoided due to inferior separation performance.
In general, a balanced ratio of analytical and experimental time allows a more efficient
use of the HTE platform. The goal was to achieve an assay time of maximum two minutes.
This would facilitate an 24 hour experiment-analysis cycle for PEGylation screenings in 96
well HTE format, where screening experiments which are performed during day time can be
analyzed over night. Further, fast assays can be useful for PEGylation reaction monitoring
and subsequent purification process monitoring.
2 Methods and materials
2.1 Chemicals
Potassium phosphate, potassium chloride and analytical grade ethanol for SEC buffer prepa-
ration were purchased from Merck (Darmstadt, Germany). Lysozyme was purchased from
Sigma-Aldrich (St. Louis, MO, USA). Methoxy-PEG aldehyde with an average molecular
weight of 5 kDa was provided from NOF Cooperation (Tokyo, Japan). Sodium phosphate,
sodium chloride and sodium cyanoborohydride (NaCNBH3) for PEGylation buffer and IEC
buffer preparation were purchased from Merck (Darmstadt, Germany).
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2.2 PEGylated lysozyme
2.2.1 PEGylation Reaction
Lysozyme (5 g/L) and PEG were dissolved in a 25 mM sodium phosphate buffer pH 7.2,
containing 20 mM sodium cyanoborohydride. The molar polymer to protein ratio was set to
6:1. The reaction was carried out in a continuously shaken falcon tube at room temperature,
for 10 h.
2.2.2 Preparative separation of lysozyme PEGamers
Single lysozyme PEGamers were purified using cation exchange chromatography. Toyopearl
GigaCap S-650M resin (Tosoh Biosience GmbH, Stuttgart, Germany) was packed in an
Omnifit glass column (25 mm x 400 mm, Diba Industries Ltd., Cambrigde, UK) according
to the manufacturer’s protocol. The resulting bed volume was 13.4 mL. A gradient elution
was performed at a flow rate of 0.7 mL/min with 25 mM sodium phosphate buffer pH 7.2
as mobile phase. After column equilibration, 50 mL sample mixture was loaded onto the
column. Elution was performed with a gradient from 0 to 200 mM sodium chloride over 21
column volumes. The fractionation volume was set to 5 mL.
2.2.3 Molecular weight determination
Resulting peak fractions were analyzed with respect to lysozyme PEGamer sizes using com-
bined size exclusion chromatography (SEC) and light scattering (LS). This analysis was
conducted using an A¨KTA Ettan system from GE Healthcare (Uppsala, Sweden) in com-
bination with a Dawn Heleos 8+ multi-angle light scattering detector and an Optilap rEX
refractive index (RI) detector, both from Wyatt Technology (Santa Barbara, USA). For SEC
a Superdex 200 GL10/300 (GE Healthcare, Uppsala, Sweden) with a mobile phase of 25 mM
sodium phosphate, pH 7.0, containing 150 mM NaCl was used. The flow rate was set to
0.8 mL/min. Injection volumes between 50 and 100µL were chosen. After UV absorbance
monitoring at 280 nm, each sample was measured by LS and RI detection. Molecular weight
(Mw) and hydrodynamic radius (Rh) calculation were calculated using the ASTRA software
(v.5.3.4.18).
2.3 Chromatography system setup
An UltiMate3000 RSLC x2 Dual system from Dionex (Sunnyvale, CA, USA) was used for
UHPLC analysis. The system was composed of two HPG-3400RS pumps, a WPS-3000TFC-
analytical autosampler and a DAD3000RS detector. The autosampler was equipped with
a 5µL sample loop. The volume of the injection needle was 15µL and the syringe size
was 250µL. For control of the UHPLC equipment and for data evaluation the Chromeleon
software (6.80 SR10) was used. The software was extended by an additional time base.
This enables a virtual separation of the LC system in two parts which can then be con-
trolled separately. Such a setup is necessary in order to facilitate separate data recording
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of each analyzed sample when performing SEC in interlaced mode. A thorough descrip-
tion of this setup and the performance of interlaced chromatography has been described by
Farnen et al. [9] and Diederich et al. [8].
2.4 Size exclusion chromatography
SEC columns (Zenix SEC-300) were purchased from Sepax Technologies (Newark, DE, USA).
The Zenix SEC-300 phase is a silica based material with a hydrophilic coating. The 3µm
sized particles have a nominal pore size of 300 A˚. Columns of the dimensions 4.6x150 mm
and 4.6x300 mm were used. The short colum was operated with a flow rate of 0.6 mL/min
and the long column with a flow rate of 0.4 mL/min. The columns were mounted with
0.2µm Opti-Solv R©EXPTM inlet filters (Optimize Technologies, Oregon City, OR, USA). For
analysis, 5µl sample was injected via full loop injections and a 250 mM potassium phosphate
buffer at pH 6.8 with 200 mM potassium chloride was used as running buffer. To prevent
fouling of the columns due to PEG binding, 10 % (V/V) analytical grade ethanol was added
to the buffer. Interlaced injection mode was performed in order to eliminate lag time between
injection and elution of the first sample components.
2.5 Multivariate calibration
Where nothing else is stated, the multivariate regression models were calibrated with six chro-
matograms: single component chromatograms of each purified lysozyme PEGamer (mono-,
di-, and triPEG) and native lysozyme, one chromatogram of all components in mass equiv-
alent ratio with respect to lysozyme, and one chromatogram of a blank injection. Chro-
matograms of the pure components and the mixture of all four components are shown in
Fig. 1A. The samples of pure components all had a concentration of 1 g/L where as each
component in the mixed sample had a concentration of 0.5 g/L. All mentioned concentration
are with respect to lysozyme.
Different multivariate regression types were applied: multilinear regression (MLR), partial
least squares (PLS) regression, and multivariate curve resolution (MCR). All data process-
ing for multivariate calibration was performed with MATLAB. For multivariate regession
with MLR and PLS, the chromatographic data was preprocessed by mean centering. All
PLS based regressions were based on 4 latent variables. MCR was performed with the
MCR-ALS algotithm. After the MCR model was calibratied with the above mentioned
six chromatograms, it was able to deconvolute overlapping chromatograms unknown to the
model. This resulted in values corresponding to the integrated aera of each pure component
present in each of the validation samples. From the initial MCR model calibration, the
relation between area and concentration was known and based hereon, the concentration of
each component in each validation sample was calculated. Hence, the MCR procedure is a
combination of a multivariate approach for chromatogram deconvolution combined with an
univariate calibration of the determined area and related concentration.
For multivariate calibrations based on integrated peak areas, calibration samples were gen-
erated according to a three layer onion design generated with MODDE (Umetrics, Sweden)
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which consisted of 32 combinations of the four components.
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Figure 1: Artificial chromatograms based on superimpositions of pure component chromatograms. These
were generated to calibrate multivariate regression models. A: overlay of single component chro-
matograms of native lysozyme and three lysozyme PEGamers (mono-, di- and tri-PEGylated). All
single component samples had a concentration of 1.0 g/L with respect to lysozyme. B–F: examples
of single component chromatogram superpositions according to the concentrations listed in the
figures.
2.5.1 Chromatographic data
Each multivariate calibrations was based either on full chromatograms or four defined points
within the chromatogram. The four points were either defined as the UV signal at the elution
volume corresponding to the peak maximum of each pure component or as the UV signal
at actual peak maxima of the recorded chromatogram (see Fig. 2, left). For the purpose of
comparison, calibrations based on integrated peak areas were also performed. Here, vertical
peak limits as well as exponential rider skimming were applied to determine peak areas (see
Fig. 2, right). Data from full chromatograms consisted of the UV the signal recorded with a
frequency of 10 Hz for the short column and 5 Hz for the long column in a defined elution
range. This range was defined as 1.4 – 1.9 mL for the short column and 2.8 – 3.75 mL for the
long column with respect to chromatograms based on conventional injection mode as shown
in Fig. 3. A full chromatogram consisted of 712 data points when generated with the long
column and 500 data points when generated with the short column.
2.5.2 Determination of calibration precision
The calibrated concentration range for native lysozyme and each PEGamer was 0 – 1 g/L
with respect to lysozyme. To determine the precision of this suggested approach for evalua-
tion of chromatograms featuring low resolution, validation samples of defined concentrations
were analyzed. The validation samples were prepared according to a three layer onion design
(designed by MODDE) which resulted in 32 samples with seven different concentration lev-
els. These samples were each injected three times and before each injection of a new sample,
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Figure 2: Schematic illustration of the different chromatographic data used for calibration. Left figure:
definition of peak maxima for calibrations based on single chromatogram data points. Right
figure: definition of peak limit for calibration based on area integration.
a blank run was performed. Based on the obtained chromatographic data, the calibrated
multivariate models were used to predict the content of each lysozyme PEGamer and native
lysozyme in the validation samples. For each model and each component the 95 % confidence
intervals were calculated based on the total of 96 analyzed samples (threefold injections of
32 validation samples). First the MATLAB ‘poly1’ fit function was used to fit a linear func-
tion to the relation between the concentration predicted by the multivariate model and the
nominal concentraion in the validation samples. After the fitting procedure, MATLAB was
programmed to return the upper and lower confidence bounds for each linear fit. Finally, the
confidence interval for each calibration and component was calculated by adding the upper
and lower confidence bound. It should be noticed that the confidence interval does not to give
excact information on the precision for different concentration levels within the calibration.
Hence, the confidence intervals were only used for comparison of the different calibrations.
To obtain more detailed information on presicion, the relative standard devaition (RDS%)
was calculated for each concentration interval (0, 0.25, 0.33, 0.5, 0.67, 0.75, and 1.0 g/L)
and presented for a selection of the most precise calibrations.
2.5.3 Dynamic and static calibration
Two modes of multivariate calibration were used. The simplest type was a static mode
where one set of pure component chromatograms recorded immediately before analysis of
the validation samples was used for calibration. However, to be able to account for systematic
changes in column performance over time, a dynamic approach was developed. In order to
do so, calibration samples were injected both before and after the analysis of the validation
samples. The regression model was then recalibrated for each validation sample based on
a linear interpolation between the chromatograms recorded before and after analysis of the
validation samples. The interpolation calculated according to equation 1:
vi,j =
n− j
n
· vi,pre + j
n
· vi,post (1)
where vi is a vector containing the recorded chromatogram of calibration samplei, n is the
total number of measured samples, and j is the number of the sample in the sample sequence
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for which the model is recalibrated. The indices pre and post indicates whether a calibration
sample was measured before or after the validation samples.
3 Results and discussion
The aim was to establish a fast SEC assay (∼ two minutes) for the quantification of lysozyme
PEGamers and native lysozyme. Hence, a type of SEC columns which allows the use of rather
high flow rates up to 3 cm/min was applied. In order to eliminate the lag time inherent in
SEC analysis, injections were performed in interlaced mode. Finally, the narrow diameter of
the chosen column type allowed for a sample size of 5µL which minimizes the time necessary
for sample injection preparation by the autosampler. All these measures resulted in an assay
time of five and two minutes for the long and the short column, respectively. These measures,
however, also caused insufficient resolution for precise quantification of all the lysozyme
PEGamers when based on determined peak areas. Therefore, multivariate calibration was
applied to achieve accurate and precise quantification despite the low resolution.
3.1 Assay time and chromatographic resolution
The resulting separation of lysozyme PEGamers using two different column lengths (150 and
300 mm) is shown in Fig. 3. The presented chromatograms result from samples injected in
traditional sequential mode and, as can be seen, less that 50 % of the recorded signal contains
relevant information. Hence, interlaced injection mode was applied to reduce the analysis
time significantly without decreasing the resolution further. The final assay for the long
column was performed with an elution volume of 2.0 mL per injected sample at a flowrate
of 0.4 mL/min. This resulted in an assay time of five minutes. The final assay for the short
column was performed with an elution volume of 1.2 mL per injected sample at a flowrate
of 0.6 mL/min. This resulted in an assay time of two minutes.
Figure 3: Separation of native lysozyme, mono-, di- and, tri-PEGylated lysozyme with two columns of
different lengths. The samples injected on the two columns were identical and contained equal
amounts of each component with respect to lysozyme. Left: separation performed on a 150 mm
column. Right: separation performed on a 300 mm column.
The determined chromatographic resolutions generated by both columns of lysozyme PEGamers
and native lysozyme are listed in table 1. These results are based on injection of equal
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amounts of the two components in question. A resolution of R & 1.5 is in general sufficient
for correct quantification based on integration of peak areas. The short column only gener-
ated sufficient resolution for native and mono-PEGylated lysozyme whereas the long column
generated sufficient resolution for all components except the tri-PEGylated lysozyme. These
results accentuate the challenging task of separating higher PEGylation forms using SEC to
a degree sufficient for quantification based on area integration. If sufficient resolution is to
be achieved for the higher PEGylation forms, a great amount of dispensable resolution will
be generated for native and lower PEGylation forms. Therefore, in order to save time, multi-
variate calibration was applied in the attempt to achieve precise and accurate quantification
despite low resolution.
Table 1: Chromatographic resolution listed for each column. Each resolution was determined by injecting
equal amounts of the two components in question.
column chromatographic resolution
length native mono-PEG di-PEG tri-PEG
300 mm 2.72 1.47 0.79
150 mm 1.66 0.98 0.35
3.2 Calibration precision
Multivariate models were calibrated based on multilinear regression (MLR), partial least
squares (PLS) regression, and multivariate curve resolution (MCR). The results of the MCR
were very similar to those of MLR and are therefore omitted. Further, traditional quan-
tification based univariate calibration of determined peak areas was performed in order to
compare multivariate calibration with the traditional approach. Finally, MLR calibration
based on peak areas and peak heights was applied to investigate whether low peak resolution
could be compensated by multivariate calibration of these parameters.
Confidence intervals were used to compare the precision of the different calibration ap-
proaches, both with regard to regression type and the data used for calibration (i.e. full
chromatograms, peak maxima, peak areas). For this purpose, the mean confidence inter-
val of the two components with the lowest chromatographic resolution was determined, in
this case the di- and tri-PEGamers. The results are listed in table 2 and are presented and
discussed in the following sections.
3.2.1 Static calibration
In general, a clear increase in precision was achieved by applying static multivariate calibra-
tion of chromatographic data. For the long column, the precision increased from 0.0476 g/L
to 0.0155 g/L by applying MLR to full chromatogram data instead of univariate calibration
of peak areas. Based on equivalent calibration for the short column, an increase in precision
from 0.0580 g/L to 0.0247 g/L was achieved. For the stronger overlapping peaks generated
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Table 2: Calibration results presented in order of precision. Different regression types were used to cali-
brate multivariate models based on different chromatogram data for evaluation of analytical chro-
matograms. The resulting confidence intervals are listed for each of the different regression types
along with model mode and the applied chromatogram data. Further, results based on traditional
area integration and univariate calibration are listed. See Fig. 2 for a schematic illustration of the
different applied chromatogram data.
regression model data confidence
type mode range interval
300 mm column
MLR static full chromatogram 0.0155
MLR static peak maxima1) 0.0164
MCR static full 0.0167
PLS static full chromatogram 0.0186
MLR static peak maxima2) 0.0206
MLR static peak area3) 0.0394
Univ. static peak area3) 0.0476
Univ. static peak area4) 0.0768
150 mm column
MLR static peak maxima1) 0.0226
MCR static full 0.0226
MLR static full chromatogram 0.0247
PLS static full chromatogram 0.0347
MLR static peak area3) 0.0453
MLR static peak maxima2) 0.0491
Univ. static peak area3) 0.0580
MLR dynamic peak maxima1) 0.0164
MLR dynamic full chromatogram 0.0167
MCR dynamic full 0.0173
PLS dynamic full chromatogram 0.0191
1) signal height to base line at retention volumes corresponding to
peak maxima of pure components
2) signal height to baseline at peak maximum
3) vertical peak limits
4) exponential rider skimming
by the short column, MLR calibration based on only four points in the chromatogram (ob-
tained at VR of the pure components) resulted in a more precise calibration with a confidence
interval of 0.0226 g/L. MLR gave more precise results than PLS both for the long and the
short column. Further, MLR calibration based on peak areas was more precise than uni-
variate calibration of peak areas, however much less precise than calibration based on full
chromatogram data. MLR calibration based on peak heights at peak maxima was more
precise than MLR calibrations based on peak areas for the long column, however the oppo-
site was the result for the short column. The elution profiles of the pure components (see
Fig. 4) shows that severe peak overlapping was limited to approximately 50 % for the long
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column. Therefore the position of peak maxima was less influenced by the presence of other
components when comparing the long column with the short column.
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Figure 4: Overlay of single component chromatograms before and after the analysis of 140 test samples.
Top: 300 mm column. Bottom: 150 mm column.
3.2.2 Dynamic calibration
The precision of the univariate peak area based calibration decreased by ∼ 25 % when com-
paring the results obtained by the long column to those obtained by the short column.
In comparison, the precision of the multivariate calibration based on MLR and full chro-
matograms decreased by ∼ 70 %. Even though the absolute value of the determined con-
fidence interval was still several times lower for the multivariate calibration compared to
univariate calibration(0.0247 vs. 0.0580 g/L) when using the short column, the relatively high
decrease in precision of the multivariate calibration when switching from the longer to the
shorter column (e.g. 0.0155 vs. 0.0247 g/L) was not expected. In Fig. 4A an overlay of pure
component chromatograms recorded before and after analysis of the 140 samples on the long
column is shown. The data shows stable column performance without a systematic change in
peak height or retention volume over time. Fig. 4B displays the equivalent data for the short
column and here a shift in retention time for all components along with peak broadening can
be observed. To overcome the inaccuracy caused by the change in column performance, a
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dynamic calibration approach was used. This calibration was based on linear interpolation
of calibration samples measured immediately before and after the analysis of the validation
samples. It was chosen to apply linear interpolation as the observed change in retention time
was linear. The use of dynamic calibration for the short column resulted in an assay of similar
precision compared to the static calibration of the long column (0.0167 vs. 0.0155 g/L).
In Fig. 5 the chromatogram residuals of the validation sample chromatograms are dis-
played. The shown residuals are derived from both the dynamic and the static PLS cali-
bration for the short column based on the full chromatograms. The variation of the chro-
matogram residuals remains constant over the period of analysis for the dynamic calibration,
where as the variation increases throughout the period of analysis for the static calibration.
This supports the decision to use linear interpolation for the dynamic calibration.
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Figure 5: Residuals of the 140 test sample chromatograms as a function of injection order. Each data point
represents one sample either evaluated with a static or a dynamic PLS based calibration model.
In order to visualize the effect of dynamic calibration, three artificial chromatograms were
created and displayed along with a true chromatogram of a validation sample ( Fig. 6). Two
of the artificial chromatograms were based on the calibration samples either analyzed before
or after the analysis of the validation samples. Neither of these chromatograms is of good
resemblance to the validation sample chromatogram. The third artificial chromatogram
was based on the linear interpolated chromatograms of the calibration samples which were
created for the dynamic calibrations. This chromatogram was built to match the point in
time where the displayed true chromatogram was recorded and exhibits a high resemblance to
the true validation sample chromatogram. For the right peak (monoPEG-protein conjugate),
the resemblance is high both for peak intensity and peak shift. The fact that the left peak
of the sample chromatogram deviates from the dynamic calibration chromatogram in peak
intensity is most likely due to a pipetting error during preparation of the validation samples.
Publications and Manuscripts
56
0.1 0.2 0.3 0.4 0.5 0.6
0
10
20
30
40
50
60
70
model1 sample model 2 dynamic model
A
2
2
5
(m
A
U
)
Elution volume (ml)
0.36 0.37 0.38 0.39 0.40
50
52
54
56
58
60
0.23 0.24 0.25 0.26 0.27 0.28 0.29
28
30
32
34
36
Figure 6: Visual comparison of the effect of dynamic calibration. One true chromatogram and three artificial
chromatogram based on linear combinations of pure component chromatograms are displayed.
Two of the artificial chromatograms were built from the pure component chromatograms recorded
either before (artificial 1) or after (artificial 2) analysis of the validation samples. The third
artificial chromatogram (artificial D) was built from the linear interpolations used in the dynamic
calibrations. The linear interpolation was built to correspond to the point in time where the true
samples was analyzed.
3.2.3 Concentration related precision and sensitivity
The concentration related precision was determined for the dynamic and static MLR cali-
brations based on the short column and the MLR calibration based on the long column. The
relative standard deviation (RSD%) for each concentration is displayed in Fig. 7. The dis-
played RSD% values are mean values of the RSD% for di- and tri-PEGylated lysozyme. For
all three calibrations, the precision increased from the first to the second concentration level
(0.25 – 0.33 g/L). For all concentration levels, the precision of the static MLR calibration
based on the 150 mm column was lowest (RSD ∼ 3 – 1.5%). The precision for all concentra-
tion levels was similar for the dynamic MLR calibration based on the 150 mm column and
the static MLR calibration based on the 300 mm column. This is in accordance with the
finding that the overall precision of these calibrations were similar (95% confidence interval:
0.0167 g/L and 0.0155 g/L, see Table 2). This means that both the overall precision and
the specific precision achieved for the long column can be maintained for the short column
by applying multivariate calibration. For further comparison and characterization of the
calibrations, the limit of quantification (LOQ) was determined. LOQ was determined as
six times the standard deviation of all zero predictions in the calibration samples for each
component. Again, the displayed LOQ values are mean values of the determined LOQ value
for di- and tri-PEGylated lysozyme. With regard to the LOQ value, the dynamic approach
does increase the sensitivity of the method, however not to the level of the MLR calibration
based on the 300 mm column.
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Figure 7: RSD % values for the concentration levels included in the validation sample design. Displayed are
mean values of the determined RDS % for di- and tri-PEGylated lysozyme. The value dispayed
for the concentration zero (grey bar) are LOQ values. Also the LOQ values are mean values of
the determined LOQ for di- and tri-PEGylated lysozyme.
4 Conclusion and outlook
The aim of establishing an SEC assay for the quantification of lysozyme PEGamers with
an analysis time of two minutes was achieved. The presented work clearly demonstrates
that by applying multivariate calibration for the quantitative evaluation of badly resolved
chromatograms the precision can be enhanced significantly when compared to traditional uni-
variate calibration. Hence, fast chromatographic assays can easily be achieved by applying
short columns and fast flow rates. The tested chromatographic assays included resolutions
down to 0.35 demonstrating how little resolution is actually sufficient to achieve a highly
precise chromatographic assay. The lower limit of resolution necessary for precise calibra-
tion is still to be determined. Further, the results demonstrated that a change in column
performance over time can be handled without difficulty by using a dynamic calibration
approach.
In the presented work, pure samples were used for calibration. If pure material is at hand
or easily achievable, this is the most straightforward approach. If pure samples are difficult
or impossible to obtain, mixed samples of defined composition can also be used. This then
requires an alternative assay or analytics to define the mixed samples and which must contain
sufficient variation.
The use of multivariate calibration is of course not limited to SEC. Any robust chromato-
graphic assay established for defined samples can be evaluated by the presented approach.
The approach cannot be applied to complex samples in which unknown peaks occur in the
area used for calibration and also chromatographic assays based on non-linear chromatog-
raphy will demand more sophisticated multivariate calibration of non-linear nature. This
might increase the calibration complexity to a level which is no longer leveraged by the
gained increase in assay speed. However, this is still to be investigated.
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In working environments with limited time for assay development and data evaluation, it
might be an unmanageable task to perform data evaluation not inherent in the chromatogra-
phy system software. Hence, we propose the integration of multivariate calibration directly
in the commercial software supplied with the chromatography systems.
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Abstract
Since the first FDA approval of a PEGylated product in 1990, so called random PEGy-
lation reactions are still used to increase the efficacy of biopharmaceuticals and represent
the major technology of all approved PEG-modified drugs. However, the great influence
of process parameters on PEGylation degree and the PEG-binding site results in a lack
of reaction specificity which can have severe impact on the product profile. Consequently,
reproducible and well characterized processes are essential to meet increasing regulative re-
quirements resulting from the Quality-by-Design (QbD) initiative, especially for this kind of
modification type. In this study we present a general approach which combines the simple
chemistry of random PEGylation reactions with high throughput experimentation (HTE) to
achieve a well-defined process. Robotic based batch experiments have been established in a
96-well plate format and were analyzed to investigate the influence of different PEGylation
conditions for lysozyme as model protein. With common SEC analytics highly reproducible
reaction kinetics were measured and a significant influence of PEG-excess, buffer pH and
reaction time could be investigated. Additional mono-PEG-lysozyme analytics showed the
impact of varying buffer pH on the isoform distribution, which allowed us to identify optimal
process parameters to get a maximum concentration of each isoform. Employing Micrococcus
lysodeikticus based activity assays, PEG-lysozyme33 was identified to be the isoform with
the highest residual activity, followed by PEG-lysozyme1. Based on these results, a control
space for a PEGylation reaction was defined with respect to an optimal overall volumetric
activity of mono-PEG-lysozyme isoform mixtures.
Keywords: PEGylation, lysozyme, high throughput process development, high
throughput experimentation, Quality-by-Design
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1 Introduction
Nowadays, recombinant proteins and peptides represent a large share of successfully ap-
proved drugs, gaining an increasing importance as therapeutics [1]. However, limitations
such as rapid body clearance, aggregation and enzymatic degradation are still major draw-
backs in the development of new biopharmaceuticals. PEGylation, the covalent attachment
of polyethylene glycol (PEG) to biopharmaceuticals has been shown to overcome such ob-
stacles and is widely used for improving therapeutics efficacy, especially for small, parenteral
administered proteins. Reasons for the great success are the numerous positive effects accom-
panied by polymer modification, which mostly include improved solubility, enhanced thermal
and proteolytic stability as well as reduced immunogenicity [2–5]. One of the major advan-
tages of PEGylated products comprises the reduced renal clearance and thus an increased
body residence time, resulting in a reduced dose administration. The altered physicochem-
ical characteristics can mostly be attributed to an increased hydrodynamic radius and the
protective effect of the attached polymer chains, and were object of intense research in the
last four decades [6–8].
With respect to increasing regulative requirements in modern pharmaceutical production
by means of reproducibility and product consistency, site-specific PEGylation is of grow-
ing interest. Proteins with a single PEG attached to a specific site are easy to purify and
represent well defined products, offering a defined activity profile. Approaches for specific
modification include for example enzymatic techniques such as glycoPEGylation and trans-
glutaminase mediated modification or an attachment via introduced binding sites [9–11].
However, such techniques are non-trivial and demand for a time consuming development. In
addition all approaches are still in development or clinical phase and a fast FDA approval
especially for genetically introduced binding sites might be problematic.
In contrast to the site specific approach, so called random PEGylation reactions were suc-
cessfully used in most instances of already approved PEGylated products, such as PEGylated
interferon and epoetin (Pegasys R© and Micera R© by Hoffman-LaRoche, respectively). Acy-
lating derivatives such as N-hydroxysuccinimidyl activated PEGs (PEG-NHS) target amino
and hydroxyl residues of surface amino acids, including lysine, histidine or serine [12, 13].
Yielding amide or urethane bonds, this reaction type reduces the protein charge by the num-
ber of attached PEG chains. Alkylating reactions such as PEG-aldehyde exclusively reacts
with the -amino side chains of lysine or the N-terminal α-amino group, leading to secondary
amines, preserving the protein charge [13–15]. A major advantage of random reactions com-
prises the simple chemistry and the availability of binding sites to provide PEG attachment,
without the need of an additional modification of the target molecule. Due to the established
status, so called fast track designations by the FDA can reduce the time to market of new
PEGylated products, if the non-PEGylated counterpart has already been approved [6].
However, as lysine residues are generally well represented in proteins, PEG-aldehyde and
PEG-NHS reactions mostly result in complex mixtures of different conjugates, varying in
number (PEGamers) and binding site (isoforms) of attached PEG. Additionally, all formed
conjugates mostly offer a reduced activity compared to the native protein, depending on
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number, size and even modification site of attached PEG, due to steric hindrance by the
attached polymer chains. Thus, each type of conjugate can offer a different specific activity,
which still provides the basis of the therapeutic efficacy. As the rate of residue modifica-
tion can be influenced by the exposure and the nucleophilicity of the binding site, reaction
conditions such as buffer pH and PEG excess can have a major influence on reaction veloc-
ity, PEGamer formation and isoform distribution. Consequently, batch-to-batch variations
in the PEGylation reaction regarding important parameters result in deviations concerning
PEGamer and isoform formation and thus affecting the overall activity of the product. The
recall of five batches of PEG-asparaginase (Oncaspar R©, Enzon) between 2000 and 2003 due
to deviations in activity [16, 17] underlines the issues of random PEGylation reactions in a
QbD driven environment.
To overcome such drawbacks, HTE combined with high sensitive isoform analytics can
be applied and to gain a deeper process understanding and thus to increase reproducibil-
ity. Additionally, adjusting process parameters can help to improve the process towards
a favorable product. Applying a low buffer pH value at PEG-aldehyde reactions, for ex-
ample, the isoform distribution can be shifted to a predominant N-terminal modification,
due to the difference of the pKa values of the - amino groups compared to the N-terminal
α-amino residue. This was successfully applied in the development of a PEG-modified G-
CSF, (Neulasta R©, Amgen) resulting in the first FDA approved mono-PEGylated protein on
market. However, an N-terminal modification does not necessarily result in an isoform with
the highest residual activity. Another approach would consequently include the screening
of PEGylation conditions towards maximal activity of the product, which might consist of
multiple isoforms. For a fast monitoring and screening of PEGylation reactions, size based
separation with an improved data evaluation using multivariate data analysis is available
[18] and can be used to optimize reaction conditions in a first step. A screening approach
regarding the modification of lysozyme with PEG-aldehyde was shown by Moosmann et al.
[19]. However this work is only focused on PEGylation degree because of missing isoform
analytics and did not use modern methods of experimental design.
The presented study describes a systematic screening method to optimize random PE-
Gylation reactions towards a maximum volumetric activity and to increase batch-to batch
reproducibility using a high throughput platform and follows a general trend where HTS is
implemented in process development [20]. Varying process parameter such as pH and pro-
tein to PEG ratio, lysozyme PEGylation kinetics with PEG-aldehyde concerning different
PEGylation degrees were generated. Using isoform analytics of mono-PEG-lysozyme pub-
lished recently [21], concentrations of each isoform were determined and combined with a
Micrococcus lysodeikticus based activity assay. According to that, isoforms PEGylated at
lysine 33 were found to exhibit the highest activity, followed by lysine 1 modified isoforms.
The results were then used to define a parameter control space for the maximal volumetric
activity of mono-PEG-lysozyme isoform mixtures, to show the potential for an industrial
application.
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2 Materials & methods
2.1 Chemicals
Methoxy-PEG-propionaldehyde (mPEG-aldehyde) and methoxy-PEG-succinimidyl carboxy-
methyl (mPEG-NHS) both with an average molecular weight of 5 kDa were provided by
NOF Cooperation (Tokyo, Japan). Hen egg white lysozyme, L-lysine as well as buffer
components including sodium phosphate, sodium chloride, potassium phosphate, potassium
chloride and sodium cyanoborohydride (NaCNBH3) were obtained from Sigma–Aldrich (St.
Louis, MO, USA). Cyclohexylaminobutansulfonic acid (CABS) was used for pH-gradient
buffer preparation and was provided by Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA). Lyophilized cells of Micrococcus lysodeikticus for lysozyme activity measurements were
provided by Sigma–Aldrich. All solutions were prepared with ultrapure water provided by
an Arium pro water purification system from Sartorius Stedim (Goettingen, Germany). For
chromatography runs, buffer solutions were additionally filtered using 0.2 µm cellulose acetat
membrane filters from Sartorius Stedim.
2.2 Apparatus
The automated PEGylation screenings were performed on a Freedom EVO R© 200 liquid han-
dling station from Tecan (Crailsheim, Germany). For pipetting, the system is equipped with
eight fixed tips and a 96-channel liquid handling arm. The system is additionally outfit-
ted with an automated plate handling arm and an integrated rotational shaker (Te-shake,
Tecan). The activity assay as well as protein concentration measurements were conducted
with an Infinite M200 plate reader from Tecan. All chromatography steps were conducted
on an A¨kta Ettan system from GE Healthcare (Uppsala, Sweden). For molecular weight
determination a Dawn Heleos 8+ multi angle light scattering device in combination with an
Optilab rEx refractive index detector, both from Wyatt Technology (Santa Barbara, CA,
USA) were used. Thermal stability assays were realized using an DynaPro Plate Reader also
from Wyatt Technology.
2.3 Software
The robotic station was operated using the Evoware 2.0 SP1 standard software from Tecan.
The import of pipetting volumes was handled via Excel (Microsoft, Redmont, WA, USA).
Controlling of the chromatography system as well as the determination of UV areas was done
using the Unicorn 5.11 software package from GE Healthcare. All calculations and visual-
izations were realized with Matlab R2011a (The Mathworks, Natick, ME, USA). The Infinte
spectrophotometer was controlled using the i-control 1.9 software from Tecan. The ASTRA
Software (version 5.3.4.18) was used for molecular weigth determination, DLS experimets
were evaluated with the Dynamics software (version 7.1.5) both from Wyatt Technology.
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2.4 PEGylation conditions
Lysozyme modifications with mPEG-aldehyde and mPEG-NHS were conducted under vari-
ous reaction conditions. For all PEGylation reactions, the lysozyme concentration was kept
constant at 4 mg/mL. All buffer systems were composed of a 25 mM sodium phosphate buffer
system with 150 mM sodium chloride. For mPEG-aldehyde reactions, 20 mM NaCNBH3 was
added as reducing agent additionally. Buffer pH values were varied in three steps ranging
from 6.2 to 8.2. In addition three different protein to PEG ratios were screened including
0.15, 0.25 and 0.35, resulting in nine different buffer conditions in total. To obtain kinetic
data for mPEG-aldehyde reactions, eight samples with reaction times from 1.5 h to 12 h
were prepared for each buffer condition.
2.5 Automated PEGylation screening
The mPEG-aldehyde PEGylation screenings were performed on the robotic workstation and
were conducted in 96-well polypropylene microtiter plates (MTP) with a total well volume
of 360 µL from Greiner Bio-One (Kremsmu¨nster, Austria). Correct liquid handling was
guaranteed by using different liquid classes for buffer, PEG and protein solutions, respec-
tively. Liquid class calibration was done by pipetting onto an analytical balance according
to Oelmeier et al.[22]. All reactions were carried out with 300 µL sample volume and varying
reaction conditions as described in the PEGylation conditions section. Buffer stock solutions
were pipetted in each well of a plate row and were mixed with a corresponding volume of
mPEG-aldehyde and lysozyme stock solutions. After 1.5 h of incubation on the rotational
mixer, the same reaction preparations were placed in the row below. This procedure was
repeated eight times, to obtain kinetic data. During incubation, the plates were covered to
avoid evaporation. To prevent a further reaction of the samples while PEGylation degree
analysis, all mPEG-aldehyde reaction preparations were terminated with lysine according to
Ottow et al. [23]. For this, a 200 mM lysine solution was added (1:1), using the 96-channel
liquid handling arm. Resulting protein concentration in all preparations were thus 2 mg/ml,
containing 100 mM lysine.
2.6 Manual PEGylation screening
Lysozyme PEGylation samples using mPEG-NHS were prepared manually in 15 ml standard
tubes, with a total sample volume of 5 ml. To account for fast hydrolysis of mPEG-NHS
in aqueous solutions [13, 24], PEG was directly diluted in corresponding lysozyme buffer
solutions, as described in the PEGylation conditions section. Due to fast reaction behaviour,
kinetic data was not evaluated for this modification type.
2.7 Analytical procedure
2.7.1 PEGamer separation
Employing the PEGylation degree analysis, the reaction preparations were analyzed with size
exclusion chromatography (SEC) using a Zenix
TM
SEC 300 column from Sepax Technologies
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Inc. (Newark, DE, USA). As running buffer a 250 mM potassium phosphate with 200 mM
potassium chloride, pH 6.8 containing 10 % ethanol was used. The flow rate was set to
0.4 mL/min and an injection volume of 5 µL was applied. For mono-PEG lysozyme sample
fractionation a Superdex 200 GL10/300 (GE Helathcare, Uppsala, Sweden) with a mobile
phase of 25 mM sodium phosphate, pH 7.2, containing 150 mM NaCl was used. The flow
rate was maintained at 1.0 mL/min and injection volumes between 100 µL and 250 µL were
chosen. The PEGylation degree was validated applying molecular weight determination with
combined light scattering and refractive index analysis.
2.7.2 Isoform separation
Isoform separation was conducted as previously reported on a MonoS 4.6/100 column from
GE Healthcare [21]. Sample volumes between 100 µL and 150 µL of purified mono-PEG
lysozyme were injected. For pH-gradient elution 20 mM CABS was used as buffer component.
Running buffer A and elution buffer B were titrated with 4 M NaOH to pH 10.6 and pH 11.6,
respectively. The elution was applied with a linear gradient ranging from 0% to 100% buffer B
over 12 column volumes (CV). The flow rate was set to 1.5 mL/min. To obtain samples for the
activity assay, resulting peaks from mono-PEGaldehyde-lysozyme isoforms were fractionated
with a constant volume of 250 µL. The fractions of multiple runs were pooled to reach
sufficient amount of single isoforms.
2.7.3 Lysozyme activity assay
For lysozyme activity measurements a tubidometric assay based on a Micrococcus lysodeik-
ticus suspension was used. For determination of protein concentrations UV absorption at
280 nm was measured in standard UV cuvettes. Activity measurements were performed in
a 96-well microplate format according to Lee et. al [25], using UV-star flat bottom plates
from Greiner Bio-One (Kremsmu¨nster, Austria). The lysozyme assay was conducted with
protein sample concentrations in the range of 1 µg/mL to 5 µg/mL to ensure linear decrease
in turbidity. To provide PEG-lysozyme isoform samples, pooled fractions collected with pH
gradient chromatography were transferred to VivaSpin 20 ultrafiltration units (Sartorius Ste-
dim, Gerrmany) with a molecular weight cutoff of 5 kDa. Each sample was diafiltrated into
25 mM sodium phospahte buffer with pH 7.2. Micrococcus cells were suspended in 25 mM
sodium phosphate buffer, pH 7.2 in a concentration of 0.3 mg/mL. Protein solutions, includ-
ing native lysozyme and PEG-lysozyme isoform samples (50 µL) were pipetted in microplate
wells and were mixed with 200 µL cell suspension. Absorption of light at 450 nm wavelength
was measured in 1 min intervals for 7 min (native lysozyme) and 20 min (PEG-lysozyme
isoforms), respectively. To prevent cell settling, the plate was shaken between the measure-
ments. The lytic activity was evaluated, calculating the negative slope of the UV450 signal.
A decrease in absorbance of 0.001/min was defined as one unit in accordance to Lee et al.
and Freitas et al. [25, 26].
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2.7.4 Thermal stability studies
Dynamic light scattering (DLS) experiments were conducted to evaluate the thermal stability
of PEGamer variants, modified with mPEG-aldehyde. Fractionated and pooled samples of
mono- and di-PEG-lysozyme were diafiltrated in 25 mM sodium phosphate buffer, pH 7.2,
and concentrated to 1.5 mg/mL. Sample volumes of 30 µL covered with 10 µL paraffin,
were placed in black 384-well plates from Corning Inc. (Corning, NY, USA). Subsequently,
a temperature ramp from 25 ◦C to 80 ◦C was carried out with a rate of 0.4◦C/min. The
maximal temperature was limited to 80 ◦C by the instrument.
3 Results and discussions
Optimization of random PEGylation processes is still a challenging task, due to missing
isoform analytics and the manifold influence of numerous reaction parameters. Thus, the
overall aim in this study was to achieve a better process understanding applying robotic based
screening of PEGylation conditions in combination with a high sensitive isoform analytics.
As model protein lysozyme was used, providing six lysine residues and thus allows PEGamer
and isoform formation with amino coupling PEG reagents.
3.1 mPEG-aldehyde
In total 72 samples were prepared for mPEG-aldehyde PEGylation, varying in buffer pH,
protein to PEG ratio and reaction time. All samples were prepared at least in triplicates.
3.1.1 Reaction termination
In order to achieve reproducible kinetic data, all mPEG-aldehyde reactions were terminated
after sample preparation to inhibit further reaction while PEGylation degree analysis and
mono-PEG lysozyme fractionation. For this, a lysine solution was used, as described by Ot-
tow et al. [23]. To investigate a suitable concentration, capable of stopping the PEGylation,
different amounts of lysine were added to a reaction preparation. As worst case scenario,
a reaction directly after PEG addition, with the highest PEG excess (0.15 protein to PEG
ratio) and a buffer pH of 6.2 was chosen. After a reaction time of 20 h, the formation
of PEG-lysozyme conjugates was evaluated, applying SEC. Figure 1 shows the impact of
varying lysine concentrations on the PEG-conjugate formation.
With a 5 mM lysine concentration, mono- and di-PEG-lysozyme conjugates were still
observable in the chromatogram. A concentration of 100 mM lysine completely stopped
the formation of mono-PEG lysozyme and was thus used in further work to terminate the
reactions.
3.1.2 PEGamer kinetics
After reaction termination, PEGamer analysis was conducted by SEC, measuring UV280
areas of native, mono-, di- and poly-PEGylated lysozyme. As mPEG-aldehyde is non–UV
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Figure 1: SEC chromatogramms of mPEG-aldehyde lysozyme reaction preparations with different lysine
concentrations after 20 h reaction time. Reaction conditions were pH 6.2 and 0.15 protein to PEG
ratio.
active, unreacted PEG could not be evaluated directly. However, the degree of PEG conver-
sion could be calculated via initial PEG concentration and formed PEG-protein conjugates.
For each buffer condition, fractions of reaction products were analyzed and obtained data
were plotted over reaction time, using exponetial fit functions as illustrated in Figure 2.
All standard deviations were below 5% and mass balances were consistently between 88%
and 100% in all sample preparations, indicating precise liquid handling and reproducibility
of the automated PEGylation. As can be seen, a constant decrease of native lysozyme is
connected with a simultaneous accumulation of different PEG-protein conjugates. Looking at
buffer preparations containing a high PEG excess, maximal fractions of mono-PEG-lysozmye
can be detected after approximately 2.5 h, followed by decrease of the formed conjugate. This
reaction behavior is in concert with publications suggesting a consecutive pseudo-first order
reaction behavior of random PEGylation reactions under conditions of a high PEG excess
[24, 27] and can be described as follows:
PEG+ protein→ mono-PEG-protein
mono-PEG-protein + PEG→ di-PEG-protein
...
(1)
Comparing the results with lysozyme reaction kinetics at pH 7 and a protein to PEG ratio
of 0.5 published by Moosmann et al. [19] a similar reaction behavior can be identified, while
the differences in reaction velocity might be explained with additional mixing and increased
PEG excess, made in this study.
To illustrate the influence of PEG excess and buffer pH, Figure 3 depicts the results for
mono-PEG lysozyme, exclusively. The contour plot was generated using a triangle based
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Figure 2: Native lysozyme and PEGamer distribution of different reaction conditions, based on SEC chro-
matograms.
cubic interpolation.
According to that, higher PEG excess as well as lower buffer pH yields a faster PEGylation
reaction. In addition, an influence of the pH on the maximal fraction of formed mono-PEG-
lysozyme was observed. However, the pH independency of lysozyme PEGylation reactions
proposed by Moosmann et al. could not be verified, as a clear influence of the buffer pH
regarding reaction velocity and maximal mono-PEG-lysozyme accumulation was found. This
underlines the importance of a systematic screening and the evaluation of sufficient data
points, as Moosmann et al. investigated the influence of different process parameters only
with ‘one factor at a time’ (OFAT) experiments for optimization purposes.
With the determination of the reaction kinetics, important process parameters such as
the PEG conversion and the selectivity for a specific conjugate were also investigated. The
highest selectivity for mono-PEG lysozyme (93 %) was found at pH 7.2 after 1.5 h with a
protein to PEG ratio of 0.35. Maximal PEG conversion of 50 % was achieved with pH 6.2,
and a protein to PEG ratio of 0.35, after 12 h.
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Figure 3: Contour plots with the fraction of mono-PEG-lysozyme, based on SEC chromatograms. Dots
show reaction conditions evaluated.
3.1.3 PEGamer stability
Protein PEGylation has been shown in numerous studies to enhance thermal stability, that
can result in improved storage behavior and extended shelf-life. An increased thermal sta-
bility was, for example, investigated by Lee et al. [2] for PEGylated interferon using turbidi-
metric methods or by Kinstler et al. [14] evaluating the aggregation level of PEG-G-CSF
over time with SEC. Measuring the hydrodynamic radius (Rh) with DLS as a function of in-
creasing temperature, the aggregation of PEGylated and native lysozyme was investigated,
in this study. Figure 4 presents the obtained results and illustrates that aggregation of
PEG-modified species occurred at higher temperatures compared to native lysozyme.
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Figure 4: Hydrodynamic radii of native and PEGylated lysozyme as a function of temperature
The improved aggregation behavior of PEGylated species can be connected with the shield-
ing effect of attached PEG molecules which prevents the interaction of hydrophobic patches.
This might imply a complete entanglement of PEG around the protein. However, recent
studies by Pai et al. [28] suggest a model where the attached PEG random coil is adjacent
to the protein.
3.1.4 Isoform distribution
All 72 prepared PEGylation samples were analyzed for their mono-PEG lysozyme isoform
distribution. For this, a recently published analysis using pH chromatography was used,
which allows an isoform separation and the identification of the corresponding PEGylation
sites [21]. Lysine 1 was identified to be the most reactive PEG conjugation site, followed by
lysine 33 using reaction buffer pH values of 7.2. A chromatogram of purified mono-PEGylated
lysozyme with the proposed elution order is shown in Figure 5.
As mono- and di-PEG conjugates co-elute using this analytics, an evaluation of crude
PEGylation mixture was not possible (data not shown). Thus, a two-step analysis was chosen
for the screenings, consisting of a mono-PEG-lysozyme fractionation using SEC, followed by
a pH gradient chromatography. Employing the described analytics, an evaluation of the
influence of buffer pH and reaction time on the isoform distribution could be achieved.
Figure 6 depicts schematically the fractions of each isoform after a reaction time of 12 h.
As can be seen, lysozyme PEGylated at lysine 1 (in the following labeld as PEG-lys1)
represents the predominant isoform at pH 6.2, while the most reactive site at pH 8.2 is
lysine 33. A correlation to this can be found at Kinstler et al. [14], where a decreasing buffer
pH led to a PEG attachment at the N-terminus. As mentioned in the introduction, this
behavior can be explained with the lower pKa value of the the α-amino residue compared
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Figure 5: Chromatogragraphic separation of mono-PEGaldehyde-lysozyme isoforms. Peak labels correspond
to PEG binding sites, according to Maiser et al. [21]
pH 6.2 pH 8.2
0
10
20
30
40
50
60
lys 96
lys 96
lys 97/116
lys 97/116
lys 13
lys 13
lys 1
lys 1
lys 33
lys 33
F
ra
c
ti
o
n
 [
%
]
Buffer pH
Figure 6: Distribution of mono-PEGylated lysozyme isoforms in dependency of the buffer pH. Both reactions
after 12 h reaction time and a protein to PEG ratio of 0.15.
to the -amino residue. In addition, for reaction mixtures at pH 6.2, the reaction time had
a significant impact on the isoform formation, which is illustrated in Figure 7.
The relative increase of PEG-lys1 over time is probably connected to the different isoform
reactivities and the formation of di-PEG-lysozyme. In this case mono-PEG-lysozyme con-
jugates are mostly formed by the attachment of PEG to lysine 1. If a mono-PEG-lysozyme
is not PEGylated at lysine 1, the most reactive site is still free for a PEG conjugation, and
reacts at first to di-PEG-lysozyme. Assuming the reaction rate from native to mono-PEG-
protein is lower than from mono- to di-PEG protein, this results in a relative increase of
lysine 1 mono-PEGylated variants.
The combination of mono-PEG-lysozyme concentration and the measured isoform frac-
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Figure 7: Isoform distribution as a function of reaction time. Reaction parameter: pH 6.2, 0.15 protein to
PEG ratio
tions allows the determination of process parameters to achieve the maximal concentration
of each isoform. This might be interesting for a pharmaceutical application, if a certain
isoform provides improved characteristics compared to other isoforms, including increased
stability or higher residual activity.
3.1.5 Lysozyme activity
First described in 1952 by Shugar [29], the lytic activity of lysozyme can be determined
by measuring the changes in turbidity of a Micrococcus lysodeikticus suspension. Figure 8
A shows the normalized linear decrease in the UV 450 nm signal of analyzed isoforms and
native lysozyme. Relative and specific activities of the evaluated samples are illustrated in
Figure 8 B and Table 1, respectively.
Table 1: Specific and normalized activity of native and PEGylated lysozyme isoforms.
Specific normalized
activity [U/mg] activity [%]
native lysozyme 22.271 100
Lys 33 7.681 35
Lys 1 5.287 24
Lys 96 3.163 14
Lys 97 & 116 3.824 17
Lys 13 3.196 14
All isoforms showed a reduced specific activity compared to native lysozyme, as expected.
Lysozyme PEGylated at position lysine 33 provided with 35% the highest residual activity,
followed by PEG-lys1 with 24%. Studies by Abe et al. [30] suggest a residual activity
of about 30% for 5 kDa mono-PEG lysozyme isoform mixtures, which is thus in the line
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Figure 8: A: normalized linear decrease in the 450 nm signal of each sample over time. B: resulting realtive
activity of each isoform, compared to native lysozyme.
with the results made in this study. As can be seen, the PEG conjugation site has an
influence on the residual activity, which corresponds to Monkarsh et al. [31] where different
activities in the range of 6% and 40% of mono-PEGylated interferon were found. Looking at
the three-dimensional structure of lysozyme, the high residual activity of PEG-lys33 cannot
be explained with steric effects of PEG, as lysine 33 is close the catalytic residues Glu 35
and Asp 52. However, the PEG structure after protein conjugation is still not completely
understood as already mentioned in the PEGamer stability section. In addition, differences in
isoform activity might be explained with altered charge distributions on the protein surface,
which plays an important role in enzyme-substrate binding mechanisms.
3.2 PEGylation conditions for a QbD approach: two case studies
In the development of pharmaceutical applications, reproducible processes and the delivery
of a product with a constant activity profile represents an important aspect. The definition
of control and design spaces can help to achieve this aim and is mandatory for regulatory
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approval since the QbD initiative by the FDA and the International Conference on Harmon-
isation (ICH), respectively. In spite of possible variations in protein characteristics due to
different PEG attachment sites, isoform mixtures are still allowed and represent the major
product of all approved PEGylated pharmaceuticals so far. Applying a corresponding QbD
approach to the present PEGylation reaction, isoform concentrations of mono-PEGylated
lysozyme and the specific activities of each isoform were combined to calculate the volumet-
ric activity of isoform mixtures. The obtained results were plotted as a function of buffer pH
and reaction time, as shown in Figure 9A. Accordingly, maximal volumetric activities can
be generated with reaction times of about 2 h and buffer pH values between pH 6.2 and pH
7.2, using a protein to PEG ratio of 0.15.
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Figure 9: Calculated volumetric activity of mono-PEG lysozyme isofom mixtures (A) and PEG-lys33 (B)
as a function of reation time and buffer pH. Protein to PEG ratio was 0.15.
However, products with only one isoform might be required in future for a successful ap-
proval, due to improved site–specific PEGylation approaches or better preparative isoform
purification techniques. To meet these possible requirements, an isolation of PEG-lys1 or
PEG-lys33 isoforms would appear reasonable in the present case. The corresponding design
space for PEG-lys33 is illustrated in Figure 9B, indicating different process parameter to gain
maximal volumetric activity. A further optimization of the product and the calculation of a
sweet spot could be achieved by combining the existing activity results with data from addi-
tional analytics. This could include for example isoform stability studies with the described
thermal stability analysis.
3.3 mPEG-NHS
In order to evaluate the influence of the PEG reagent regarding PEGamer and isoform for-
mation, modifications with mPEG-NHS were carried out additionally. SEC chromatograms
of the nine prepared samples showed constant PEGamer distributions after 30 min, which
implies a fast hydrolysis of the used PEG (data not shown). Figure 10 A illustrates the
obtained chromatograms of PEGylation mixtures, conducted with a protein to PEG ratio of
0.35 and varying buffer pH values.
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Figure 10: A: SEC chromatograms of mPEG-NHS modified lysozyme reaction mixtures with a Sepax
Zenix
TM
SEC 300 column, B: Comparison of the isoform elution profiles of mono-PEG-lysozyme.
Reaction buffer pH was 6.2
In contrast to mPEG-aldehyde reactions, an increased buffer pH value yields in an in-
creased formation of PEGylated species. Thus, an accelerated hydrolysis of the NHS group
or a reduced PEGylation reaction velocity can be assumed using low buffer pH values. In ad-
dition, larger PEG excess resulted in an increased accumulation of PEGylated species, which
is comparable to mPEG-aldehyde reactions (data not shown). By comparing the retention
volumes of mono-PEG lysozyme isoforms modified with mPEG-aldehyde and mPEG-NHS,
shown in Figure10 B, the latter shows a small shift to lower elution pH values. This could
be explained with the different chemistries between acylating and alkylating PEG deriva-
tives, where mPEG-NHS removes and mPEG-aldehyde preserves the charge of the amino
group. Looking at the isoforms being formed with mPEG-NHS, at least seven peaks can be
detected, indicating more binding sites in contrast to mPEG-aldehyde modifications. This
is probably connected with an additional PEG conjugation via histidine, serine or tyrosine
residues, which is possible using mPEG-NHS, as reported by Veronese et al. [12]. However,
a final identification of mPEG-NHS isoform binding sites was not conducted, as this would
exceed the scope of this manuscript. Further, an influence on the isoform distribution with
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varying pH values was not observed for the mPEG-NHS modifications (data not shown).
The additional mPEG-NHS modifications suggest a major influence of the PEG reagent on
reaction behavior and resulting PEGamer and isoforms distribution. Additional differences
between both described PEGylation methods, for example in stability or isoform activity
were not evaluated but should be taken into account when choosing the type of PEGylation.
4 Conclusion and outlook
In the present study it was shown how a classical PEGylation reaction can be optimized
with respect to maximal isoform concentration and maximal volumetric activity using high
throughput methods. The method described herein, showed that so called random PEGy-
lation reactions combined with a systematic screening approach and high sensitive analyt-
ics can result in a controlled PEGylation of a target molecule and thus can meet the FDA
guidelines regarding process understanding and reproducibility. Additional experiments with
mPEG-NHS illustrated the severe impact of a different PEG reagent on formed isoforms and
reaction behavior. Future work might focus on the mathematic modeling of described re-
actions and the influence of different reaction parameters such as reaction temperature and
PEG molecular weight.
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Abstract
The combination of PEG-protein conjugation and a chromatographic separation is generally
known as solid-phase or on-column PEGylation and can provide advantages compared to
commonly applied batch PEGylation. Even though the concept was already applied by sev-
eral authors, changes in the isoform distribution compared to liquid phase PEGylation, due
to sterically hindered PEGylation sites could not be confirmed. In this manuscript, a method
for solid-phase PEGylation experiments in a 96-well plate format, using an automated liq-
uid handling station is described. Applying size exclusion chromatography (SEC) and high
sensitive isoform analytics for mono-PEGylated lysozyme, we were able to investigate the
differences in reaction kinetics and isoform distribution between adsorber based PEGylation
and modifications in free solution. Accordingly, solid-phase PEGylation with SP Sepharose
FF and XL showed generally a reduced PEGylation reaction. In contrast to the predominant
N-terminal PEGylation of lysozyme in liquid phase, a main modification of lys 97 and lys 116
was found for solid phase experiments, which could be explained with binding orientations
on corresponding adsorbent materials. Further experiments with varying amount of bound
protein showed an influence on the isoform distribution of mono-PEGylated lysozyme addi-
tionally.
Keywords: PEGylation, lysozyme, high throughput process development, high
throughput experimentation, Quality by Design
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1 Introduction
Since four decades, attaching polyethylene glycol (PEG) to a target molecule is widely used
to modify pharmacological properties of proteins, peptides or polynucleotides and is still
the method of choice to improve the efficacy of biopharmaceuticals. Up to now, ten FDA
approved products have been entered the market [1], confirming safety and therapeutic value
of the applied method. Reported advantages of PEGylated proteins compared to unmodified
species include enhanced circulation half-life, improved stability, increased solubility and
reduced immunogenicity [2–4]. The altered characteristics can mostly be attributed to a
shielding effect of attached PEG chains resulting in a delayed renal clearance, due to reduced
proteolytic degradation and increased hydrodynamic radius [5–8]. However, these benefits
are generally attended by a reduced specific activity, which is also induced by the protective
effect of attached PEG molecules.
For protein PEGylation, so called random reactions are commonly used, targeting over-
represented amino acids such as lysine or the N-Terminus. These reactions consequently
yield complex product mixtures consisting of molecules with a different number of bound
PEG (PEGamers) and positional isoforms. However, each PEG-protein conjugate can offer
different properties with severe impact on important clinical aspects such as the final specific
activity. Significant influence of the PEG attachment site on the activity was shown for
example by Monkarsh et al. [9] where residual activities between 40% and 6% of mono-
PEGylated interferon (IFN) were analyzed. Despite of such differences, characterized isoform
mixtures are still allowed by the FDA, and provide the major product of all approved PEG-
proteins. Due to maximal residual activity and minimal number of positional isoforms,
proteins with a single attached PEG chain are thus the preferred modification type for
pharmaceutical applications. However, as the PEGamer and isoform distribution can be
influenced by process parameters such as pH and PEG-excess additionally, process control
and reproducibility of the developed PEGylation reaction is essential to avoid variations in
product configuration and thus in resulting product profile.
The standard PEGylation procedure uses batch modification of already purified and pure
protein in free solution, followed by a chromatographic separation of resulting mixture [10].
The combination of both unit operations is known as solid phase or on-column PEGylation.
It offers advantages with respect to process control, as PEGylation reaction, removal of
unwanted variants and the isolation of the target conjugate can be realized in one step. This
technique has been investigated by several authors and can be conducted in two different
ways. One approach includes the immobilization of reactive PEG molecules on adsorbent
matrices and the start of the reaction by adding proteins. Shang et al. [11] for example
adsorb PEG-aldehyde on HIC membranes in a high salt environment. After a flow-through
of lysozyme, the authors eluted mono- and di-PEGylated variants and proposed an increased
selectivity towards mono-PEG lysozyme compared to equivalent experiments in free solution.
Another approach describes the second possibility, were the target molecule is immobilized
to the adsorbent matrix and PEGylated by a flow-through of activated PEG. Lee et al. [4]
and Suo et al. [12] describe this technique for the PEGylation of interferon-α (IFN) and
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bovine hemoglobin, respectively. Both authors determined reduced multi-PEGylation com-
pared to liquid phase PEGylation, which was explained with steric effects, such as blocked
PEGylation sites.
In addition to reduced unit operations and suppressed multi-PEGylation using solid-phase
PEGylation, changes in the isoform distribution resulting from an oriented binding behavior
of proteins on the chromatographic media were also discussed, due to its important impact
on the product profile. Monkarsh et al. [13] analyzed liquid- and solid-phase PEGylated
IFN using an isoform analysis for mono-PEGylated variants. However, differences in the
distribution of formed isoforms by comparing both elution profiles could not be detected.
Studies by Baran et al. [14] reported higher residual activities of on-column PEGylated
asparaginase and catalase using dye chromatography with Red SepharoseTMin comparison
to species being PEGylated in free solution. This implies a protection of the active site due to
the on-column PEGylation and thus a different isoform composition. However, the authors
did not validate this by own experiments but compared the obtained specific activities with
liquid phase experiments provided by literature. As these reference reactions were partially
conducted with different PEGylation reactions, the improved activity profile might also be
related to the different chemistry. Thus a change in the isoform distribution could not be
confirmed finally.
In recently published manuscripts, the separation and binding site identification of mono-
PEGylated lysozyme isoforms has been discussed and the influence of buffer conditions on
the isoform distribution has been investigated [15, 16]. Based on this background knowledge,
solid-phase PEGylation of lysozyme was conducted in this study, employing automated small
scale PEGylation reactions in 96-well plates. For this, lysozyme was initially bound onto
SP Sepharose FF and XL and was subsequently incubated with mPEG-aldehyde. After
elution, reaction mixtures were analyzed for PEGamer and isoform distribution of mono-PEG
lysozyme using SEC and high sensitive pH gradient chromatography, respectively. Obtained
results showed a significant influence of the resin type on reaction kinetics. Additionally,
isoform changes compared to liquid-phase PEGylation were detected, demonstrating the
applicability of used method to screen for favorable isoform compositions.
2 Material and methods
2.1 Chemicals
Components for buffer preparation including sodium phosphate and sodium chloride as well
as hen egg white lysozyme were purchased from Sigma Aldrich (St. Louis, MO, USA). As
PEG reagent, methoxy-PEG-aldehyde (mPEG-aldehyde) with an average molecular weight
of 5 kDa from NOF Cooperation (Tokyo, Japan) was used. Sodium cyanoborohydride
(NaCNBH3) was used as reducing agent for PEGylation reactions and were obtained from
Sigma-Aldrich. For isoform separation cyclohexylaminobutansulfonic acid (CABS) was used
as buffer component and was provided by Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA). Water was provided by an Arium pro water purification system from Sartorius Ste-
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dim (Goettingen, Germany). Additional filtration with 0.2 µm cellulose acetat membrane
filters was conducted for all buffer solutions. For solid–phase PEGylation experiments the
conventional cation exchange resin SP Sepharose FF, as well as the tentacle-type resin SP
Sepharose XL were used (both from GE Healthcare, Uppsala, Sweden).
2.2 Apparatus
PEGylation experiments and isotherm binding studies were performed on a Freedom EVO R© 200
liquid handling station from Tecan (Crailsheim, Germany). The system is equipped with
eight fixed tips, a 96-channel liquid handling arm, an automated plate handling arm and
a rotational shaker (TeShake, Tecan). In addition, a centrifuge (Rotana 46RSC, Hettich,
Tuttlingen, Germany) and an Infinite M200 UV spectrometer from Tecan are integrated to
the system. To operate the robotic system, the Evoware 2.1 software from Tecan was used.
Data handling and import of pipetting volumes was realized using Microsoft Excel (Red-
mond, WA, USA). All analytical chromatography steps were conducted on A¨kta Purifer and
A¨kta Ettan systems from GE Healthcare using the Unicorn 5.1 software package for system
control and data analysis of UV signals.
2.3 Binding isotherms
In order to evaluate the capacity of used adsorbent material, adsorption isotherms were
determined. All isotherms were conducted using 25 mM sodium phosphate buffer, pH 7.2
and were performed at least in triplicates. Automated pipetting, mixing and centrifuga-
tion was carried out on the robotic liquid handling station from Tecan. Adsorbent samples
(20.8 µL) were produced with a plaque device from Atoll (Weingarten, Germany) and were
placed in 2.2 ml deep well plates from ABgene (Epsom, UK). Resin incubation with different
concentrations of lysozyme was conducted using the rotational shaker for 2 h. After cen-
trifugation with 1000 rpm for 10 min, the supernatant was transferred into 96-well UV star
plates from Greiner (Frickenhausen, Germany) and UV280 was measured with the integrated
spectrophotometer.
2.4 PEGylation procedure
Solid–phase PEGylation experiments including protein binding, PEG incubation and elution
were carried out on the liquid handling station. PEGylation experiments in free solution were
also conducted automatically as previously reported [16].
2.4.1 Protein binding
Protein loading of adsorbent material for solid–phase PEGylation experiments was conducted
as described in the binding isotherms section. The sample volume was set to 1 ml. After
incubation and centrifugation, the supernatant was analyzed, measuring UV 280 nm to
evaluate the amount of bound protein. To remove unbound protein, two washing steps with
500 µL washing buffer (25 mM sodium phosphate buffer) were conducted, including flushing,
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centrifugation and removal of supernatant. To investigate the influence of protein density on
the adsorbent surface, the surface coverage, representing the percentage of maximal binding
capacity, was varied. Different surface coverage from 50% to 100% was realized by changing
the protein concentration in the adsorbent incubation step.
2.4.2 PEG incubation
After the protein binding, loaded adsorbent particles were suspended in PEGylation buffer
(25 mM sodium phosphate buffer, containing 20 mM NaCNBH3 and mPEG-aldehyde.) and
incubated using the integrated shaker (1000 rpm). The PEG excess was kept constant by
calculating the amount of bound lysozyme and adjusting the concentration of added PEG.
The protein to PEG ratio was set to 0.15, which corresponds to a 6.6 PEG excess. To obtain
kinetic data, PEG solution was added well-by well. The PEGylation reaction was stopped
with a centrifugation step and a subsequent washing procedure using the 96-channel liquid
arm.
2.4.3 Elution
The elution of bound protein was carried out using a 25 mM sodium phosphate buffer, with
1 M NaCl. For this, adsorbent plaques were repeatedly incubated with 200 µL elution buffer
for 30 min. and supernatant was collected. 600 µL eluate was pooled for analytical purposes.
2.5 Analytical procedure
2.5.1 PEGamer separation
Pooled elution samples from solid- and liquid–phase experiments were analyzed for their
PEGamer distribution with size exclusion chromatography (SEC) using a Superdex 200
GL10/300 from GE Healthcare. As mobile phase, a 25 mM sodium phosphate buffer, pH
7.2, containing 150 mM NaCl was chosen and the flow rate was set to 1.0 mL/min. To obtain
samples for the isoform analysis, mono-PEG lysozyme was fractionated with a constant
volume of 250 µL. The PEGylation degree was previously validated applying molecular
weight determination with combined light scattering and refractive index analysis [16].
2.5.2 Isoform separation
Isoform separation was conducted on a MonoS 4.6/100 column from GE Healthcare as re-
ported in recent publication [16]. Sample volumes between 100 µL and 150 µL of purified
mono-PEG lysozyme were injected. For pH-gradient elution 20 mM CABS was used as
buffer component. Running buffer A and elution buffer B were titrated with 4 M NaOH to
pH 10.6 and pH 11.6, respectively. The elution was applied with a linear gradient ranging
from 0% to 100% buffer B over 12 column volumes. The flow rate was set to 1.5 mL/min.
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3 Results and discussions
The aim in this study was primarily to elucidate the influence of solid-phase PEGylation
on the isoform distribution and thus the possible impact on important product properties.
A second aspect was to establish a robotic based batch PEGylation method, enabling the
generation of reaction kinetics to determine the differences between solid- and liquid-phase
PEGylation. Due to numerous PEGylation studies in free solution and the knowledge about
binding orientations on different cation-exchange resins, lysozyme was used as model protein
[17–20].
3.1 Isotherms
To consider the amount of bound protein on the adsorbent surface, isotherms for both
investigated cation exchange resins were generated. The obtained isotherm data were fitted
with the Langmuir model according to Equation 1 and maximal binding capacities Qmax
were calculated as illustrated in Figure 1. Thus a capacity of 95.7 mg/mL was evaluated for
SP Sepharose FF and 157.0 mg/mL for Sepharose XL, respectively.
Q* = Qmax
Kdc
*
1 +Kdc*
(1)
With:
Qmax: maximal binding capacity
Q*: protein concentration in stationary phase
c*: protein concentration in liquid phase
Kd: equilibrium constant
Q
* 
[m
g
/m
L
]
c* [mg/mL]
0 1 2 3 4 5 6
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Figure 1: Isotherms for SP Sepharose FF and XL, both in 25 mM sodium phosphate buffer, pH 7.2. Maximal
binding capacities were calculated using the Langmuir model.
.
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Both investigated adsorbent materials offer a dextran based matrix carrying sulfopropyl
(SP) ligands for cation exchange processes. Considering the flexible chains of tentacle type
adsorbers the increased capacity of SP Sepharose XL can be connected with an increased
accessibility of the ligands compared to conventional ion exchange resins. To compare solid–
phase PEGylation reactions in the study, surface coverage was calculated and adjusted,
which represents the percentage of the maximal binding capacity.
3.2 PEGylation kinetics
If proteins with multiple attachment sites are PEGylated in free solution and the presence of
a PEG excess, native protein is modified via the most reactive site to a mono-PEG-protein
conjugate, which reacts to di- and poly-PEG-protein in further reaction process. This can
be described as a pseudo first order consecutive reaction [21, 22] and was shown for present
lysozyme reaction in a study, published recently [16]. The comparison between a reaction in
free solution and the solid-phase PEGylation using SP Sepharose FF and XL with respect
to PEGamer formation is illustrated in Figure 2. All reactions were conducted under equal
conditions, using a buffer pH of 7.2 and a protein to PEG ratio of 0.15, representing a
PEG excess of 6.6. For solid-phase PEGylation, the lysozyme surface coverage of the resin
particles was 60% and the recovery, determined by SEC, was consistently between 86% and
96%.
As can be seen, PEGylation of adsorbed lysozyme on SP Sepharose FF illustrated in
Figure 2 A shows a maximal fraction of 10% for mono-PEGylated variants after 12 h, com-
pared to a maximal value of 47% in liquid phase, after 3 h. Additionally, a formation of
di-PEGylated variants could not be observed, indicating a significant reduction in reaction
velocity for solid-phase experiments. These characteristics can be connected to different
reasons. Considering lysozyme is immobilized on the resin surface, reduced amount of ap-
propriate attachment sites due to steric hindrance by the resin surface might be possible and
is discussed in the next section. In contrast to convection driven process in free solution, the
reaction for solid-phase experiments is diffusion limited, given by film- and pore diffusion of
PEG molecules, additionally. PEGamer kinetics for solid-phase PEGylation on Sepharose
FF and XL over a reaction time of 60 h is shown in Figure 2 B and demonstrates a further
reduction in reaction kinetics for the grafted resin type compared to the conventional ion
exchange particles, which is probably based on increased protein density on the surface, and
thus reduced protein accessibility. An influence of the reaction pH on the kinetics is shown
in 3 and corresponds to former results for liquid-phase PEGylation, where decreasing buffer
pH values led to an increased reaction velocity [16]. This effect could be observed both for
SP Sepharose FF and XL (data not shown).
Comparing the solid-phase coupling kinetics made in this study with results provided by
literature, a low reaction rate towards PEG-protein conjugates could generally be noticed, as
a maximal conversion of only 37% for native lysozyme was detected after 60 h (see Figure 3).
On-column experiments by Lee et al. [4] with packed CM-Sepharose particles and PEG-
aldehyde resulted in an overall PEGylation of native IFN of 68%, after 120 min. However,
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Figure 2: PEGamer kinetics based on SEC chromatograms and plotted using exponential fit functions.
A: Comparison of liquid- and solid-phase PEGylation using SP Sepharose FF. B: Solid-phase
PEGylation with SP Sepharose FF and XL. Reaction conditions: pH 7.2, 0.15 protein to PEG
ratio, 60% surface coverage.
.
the authors used PEG concentrations up to a 40-fold excess. This consequently increases
reaction velocity, but also results in an enormous consumption of PEG. An increased reaction
rate might also be achieved by using a different PEGylation chemistry, as shown by Suo et
al. [12], where PEG-NHS was used as PEG reagent. A possibility to overcome diffusion
limitations might be the usage of monolithic columns or membranes, providing separation
performance due to porous channels rather than chromatographic particles. As opposed to
the experiments by Lee et al., a multi-PEGylation could not be avoided in this study, as
di-PEGylated variants were formed using SP Sepharose FF. To reduce the fraction of multi-
PEGylated variants the usage of PEG with an increased molecular weight and thus increased
steric hindrance should be taken into consideration.
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Figure 3: Solid-phase PEGylation kinetics on SP Sepharose FF for native and mono-PEGylated lysozyme
using reaction buffers with pH 6.2 and 7.2. Protein to PEG ratio was 0.15.
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3.3 Isoform distribution
Lysozyme consists of seven amino residues, including six lysine residues and the N-terminus.
As lysine 1 exhibits both the α- and an -amino group, six mono-PEGylated isoforms can
be formed, if mPEG-aldehyde is used. Lysozyme PEGylation studies, introduced by the
authors recently [15] showed a separation and identification of five isoforms, using pH gra-
dient chromatography. By comparing the UV areas, the N-terminus was evaluated to be
the predominant PEG-attachment site, followed by lysine 33 using buffer pH values of 7.2.
Only small reactivates were found for lys 13, lys 96 and lys 97/116. Employed solid-phase
experiments were analyzed according to their isoform distribution and were compared to
liquid-phase reactions. Chromatograms of purified mono-PEG-lysozyme, PEGylated on SP-
Sepharose FF and in free solution are shown in Figure 4.
For lysozyme immobilized during the reaction, the illustrated data suggests a main modifi-
cation of two peaks, representing lysine residues lys 13, lys 97 and lys 116, even though these
residues comprise the lowest reactivity in free solution. In addition to pore and film diffusion,
the modification of low reactive PEGylation sites can thus be seen as another aspect of re-
duced reaction velocity in the solid-phase mode. N-terminally PEGylated lysozyme (labeled
in the following as PEG-lys1) and PEG-lys33 are also formed in minimal extend, but their
fractions did not increase over time compared to the main isoforms. To explain the changes
in the isoform composition, structural considerations and lysozyme binding orientations on
ion exchange resins made by Dismer et al. [19] were used. Accordingly, main interaction
sites of lysozyme on SP Sepharose FF particles were proposed between lys 1 & lys 33, and
lys 116 & lys 33, respectively. Figure 5 illustrates a three-dimensional model of lysozyme and
depicts the possible PEGylation positions and interaction sites with the adsorbent material.
As can be seen, a resin–binding region between lys 1 and lys 33 agrees well with the results
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Figure 5: Three–dimensional model of lysozyme with labeled lysine residues. Resin interaction sites on SP
Sepharose FF according to Dismer et al. [19] are labeled with blue arrows.
.
made in this study, allowing a PEGylation of opposite-located lysine residues lys 13 and
lys 97. Additionally the reduced formation of PEG-lys1 and PEG-lys33 can thus be explained
with a sterically hindrance of corresponding lysine residues. Even though lysine 96 is exposed
to the mobile phase and thus well accessible according to the proposed binding orientation,
an increase in corresponding isoform could not be observed. A possible explanation for this
can be the higher reactivity of lys 97 compared to lys 96 in free solution, resulting in a
blocking of attached PEG at lys 97 towards lys 96.
The constant amount of PEG-lys1 and PEG-lys33 over reaction time, shown in Figure 4,
implies a formation of these isoforms at the beginning of the PEGylation and is in striking
contrast to the increase of mainly formed isoforms PEG-lys13 and PEG-lys97/116 in the further
reaction. This result can also be linked to the different lysine reactivities and accessibilities.
All available, but limited lys 33 and N-terminal amino groups are modified at first, due to
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Figure 6: Isoform distributions of solid- and liquid-phase experiments at pH 7.2 with a protein to PEG ratio
of 0.15. Solid-phase experiments show results with 60% surface coverage and 60 h reaction time
.
their increased reactivity. Further PEGylation occurs then at the residual PEGylation sites,
even though they exhibit a reduced reactivity.
Comparing solid-phase PEGylated lysozyme on SP Sepharose XL with the non-grafted
adsorbent, a similar isoform distribution with PEG-lys13 and PEG-lys97/116 as main isoforms
can be observed, as illustrated in Figure 6. Solid–phase experiments show results after a
reaction time of 60 h, while liquid phase results represent the isoform distribution after 12 h.
The different isoform distribution using SP Sepharose XL in contrast to liquid–phase PE-
Gylation is in the line with previous studies [20], where a multipoint adsorption of lysozyme
via lys 116, lys 33 and lys 1, enabled by the flexible spacer chains, was suggested. However,
the changed isoform conformation is not as clear as the results conducted with SP Sepharose
FF. This aspect might be explained with the reduced formation of mono-PEG lysozyme, as
only 3% of bound protein was modified after 60 h (see Figure 2B).
Besides the advantages in process control due to a reduction of unit operations, a pos-
sible change in the isoform composition, enabled by on-resin or solid-phase PEGylation,
were discussed by numerous authors and could be verified in this study. However, activity
measurements for the present model protein based on Micrococcus lysodeikticus cells and
conducted by the authors previously [16], showed that PEG-lys33 and PEG-lys1 exhibit the
highest residual activity. Consequently, an increase of volumetric activity for eluted iso-
form mixtures of mono-PEG-lysozyme could probably not be achieved with the used resin
material, due to its unfavorable isoform composition.
3.4 Influence of surface coverage
To investigate the influence of protein surface density on the isoform formation, varying
surface coverage in the range of 50% to 100% was evaluated. Due to limited mono-PEG-
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Reaction conditions: pH 7.2, 0.15 protein to PEG ratio, 42 h reaction time
.
lysozyme formation using SP Sepharose XL as adsorbent material, only SP Sepharose FF
was used. In Figure 7 a significant increase of PEG-lys13 isoforms from 35% to 43% with
increasing surface coverage is apparent.
This is attended with a decrease of isoforms modified at lys 1 and lys 97/116, respectively.
Considering a mono-layer adsorption of lysozyme on SP Sepharose FF with the proposed
binding site between lys 1 and lys 33, this result can be concluded of a reduced accessibility
of side-located lys 116 and lys 1 by neighboring bound lysozyme molecules.
4 Conclusion and outlook
The presented work demonstrates the impact of adsorbent based PEGylation on the PEGamer
kinetics and the isoform distribution. In contrast to reactions in free solution a significantly
reduced reaction rate to PEGylated species was observed. Additionally, a changed iso-
form distribution from a predominant N-terminal PEGylation to a distribution dominated
by PEG-lys97/116 and PEG-lys13 was observed. These findings suggest a main binding of
lysozyme on the adsorbent surface close to lys 1 and lys 33 for both investigated resins,
which is in the line with studies by Dismer et al. [19, 20].
Using lysozyme as model protein, an increase in specific activity of the isoform mixture
due to a favorable distribution could probably not be achieved, as PEG-lys1 and PEG-lys33
were investigated in former studies to be the most active isoforms [16].
However, the influence of solid-phase PEGylation on important aspects could be con-
firmed in this study and are in contrast to studies by Monkarsh et al. [13] where a change
in the isoform distribution applying on-column PEGylation of IFN could not be demon-
strated. Consequently, different binding behavior of protein on adsorbent materials and thus
changes in the isoform distribution should be taken into account if on-column or solid phase
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PEGylation is applied.
The increase of reaction rates towards PEGylated species by applying a high PEG excess
is only an option if PEG can be recycled due to high material costs. Avoiding diffusion
limitations of chromatographic particles, future work will focus on monolithic columns or
membranes as adsorbent matrix.
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4 Conclusion and Outlook
This work is focused on a detailed view of random PEGylation reactions and includes three
main aspects.
• Improved isoform separation, enabling a fast isoform identification.
• High throughput screening approach to achieve ideal reaction conditions, both for
isoform mixtures and single isoforms.
• Influence of solid-phase PEGylation on process performance and product characteris-
tics.
The essential work of this thesis was done with the development of high-sensitive isoform
analytics using pH gradient chromatography. First of all, it could be shown that the applied
model PEGylation reaction with lysozyme and PEG-aldehyde results in more than three
isoforms of mono-PEGylated lysozyme, which is contrary to numerous published studies.
Further, the correlation between calculated isoelectric points and elution pH values of sep-
arated isoforms allowed a first guess on the PEG-attachment site, which could be verified
later on by standard methods. The usability of this fast in silico method was shown in this
work only for PEG-lysozyme isoforms. Thus, the overall applicability for other PEG-protein
conjugates needs to be demonstrated in future.
The developed chromatographic isoform separation method was used in further work as a
basis to show the feasibility of HTPD with respect to an optimized lysozyme PEGylation.
Combining the improved isoform analytics and a standard lysozyme activity assay with au-
tomated and miniaturized PEGylation sample preparation, an ideal lysozyme PEGylation
process regarding maximal volumetric activity could be generated. It could be shown, that
PEG excess, buffer pH value and the process time are significant parameters, affecting the
isoform distribution and reaction velocity of PEG-aldehyde modifications. Controlling these
parameters, a reproducible process with defined product mixtures can be generated. Con-
sequently, this approach demonstrated a targeted PEG-modification of available binding
sites using high throughput techniques rather than a randomized and uncontrollable PEG-
attachment. Although the approval of PEG-protein mixtures might become more difficult
in future due to improved isoform separation techniques, well characterized “random” PE-
Gylation reactions with a subsequent isoform separation will still represent a simple and
interesting PEG modification method in contrast to difficult site-specific PEGylations.
The last aspect of this work contributes to a question, which is discussed for a long
time in the community and includes the influence of solid-phase PEGylation on the isoform
distribution. Small scale solid-phase PEGylation experiments were conducted and showed
generally a reduced reaction towards PEGylated species. Additionally, an altered isoform
distribution in contrast to reactions in free solution could be determined. In case of the
applied model reaction, this change was connected with a reduced residual activity. However,
the effect of a changed isoform distribution using solid-phase PEGylation might be interesting
for other PEG-proteins, if an advantageous isoform distribution with improved characteristics
in contrast to liquid phase PEGylation can be achieved. The first results of the solid-phase
PEGylation reactions that are presented in this thesis were used in further experiments to
establish a semi continuous on-column PEGylation process, were immobilized lysozyme was
PEGylated by a flow-through of activated PEG.
5 Abbreviations and Symbols
Abreviations
ADM age related macular degeneration
BSA bovine serum albumin
CV column volume
DLS dynamic light scattering
Fab fragment antigene binding
FDA Food and Drug Administration
GalNAc N-Acetylgalactosamine
G-CSF granulocyte colony-stimulating factor
GRAS generally recognized as safe
hGH human growth hormone
HIC hydrophobic interaction chromatography
HTE high throughput experimentation
ICH International Conference on Harmonisation
IEC ion exchange chromatography
IFN interferon
LS light scattering
MALDI matrix assisted laser desorption ionization
MALS multi angle light scattering
MCR multivariate curve resolution
MLR multilinear regression
MVDA multivariate data analysis
N nitrogen
NHS N-hydroxysuccinimidyl
pI isoelectric point
PEG polyethylene glycol
PLS partial least squares
QbD Quality-by-Design
RNA ribonucleic acid
RSD relative standard deviation
RI refractive index
SANS small angle neutron scattering
SCID severe combined immunodeficiency desease
SEC size exclusion chromatography
Tgase transglutaminase
TNF tumor necrosis factor
UV ultraviolet
VEGF vascular endothelial growth factor
Abbreviations and Symbols
Symbols
A variable [nm]
c protein concentration [mg/mL]
k number of attached PEG molecules [-]
Kd equilibrium constant [mg/mL]
Mw molecular weight [Da]
m available binding sites [-]
n total number of measured samples [-]
P number of possible isoforms [-]
Q binding capacity [mg/mL]
R resolution [-]
Rh hydrodynamic radius [nm]
VR retention volume [mL]
Greek symbols
α indicates the N-terminus
 indicates a lysine residue
Indices
i calibration sample
j sample number within the sample sequence
n number of samples
PEG PEG
PEGprot PEG-protein conjugate
pre indicates calibration before the validation samples
prot protein
post indicates calibration after the validation samples
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